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1. INTRODUCTION 
 
 1.1. NOVEL DRUG DELIVERY SYSTEM (Bankar G.S and Rhodes C.T., 
2009; Brahmankar D.M and Jaiswal S.B., 2005; Chein Y.W., 2002) 
The goal of a controlled release dosage form is to maintain therapeutic blood 
or tissue levels of the drug for an extended and specified period of time. This is 
generally accomplished by attempting to obtain "zero-order" release from the dosage 
form. Zero-order release constitutes drug release from the dosage form which is 
independent of the amount of drug in the delivery system (i.e. a constant release rate). 
Sustained-release systems generally do not attain this type of release and usually try 
to mimic zero-order release by providing drug in a slow first-order fashion   (i.e., 
concentration release dependent). Systems that are designated as prolonged release 
can also be considered as attempts at achieving sustained-release delivery. 
The term ―Controlled- release drug product‖ has been used to describe various 
types of oral extended release rate dosage forms, including sustained release (SR), 
sustained action, prolonged action, long action and retarded release. These terms for 
extended release dosage forms were introduced by drug companies to reflect a special 
design for producing an extended release (ER) dosage form or used as a marketing 
term. 
In the last two-three decades interest in sustained release drug delivery 
systems is remarkably increasing. This has been due to various factors viz. 
 Developing new drug entities. 
 Expiration of international patents 
 Discovery of new polymeric materials suitable for prolonging the drug release. 
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 Need of therapeutic efficacy and safety achieved by sustained release drug 
delivery. 
The subject of controlled release has been reviewed by various authors. 
Several books have been published on it. These reviews and books provide not only 
the mechanisms and technology of production of dosage forms but also the 
information on clinical evidence and performance. 
There are many definitions of controlled release but the simplest definition is 
―Any drug or dosage form or medication that prolongs the therapeutic activity of 
drug’’. The overall objective is that, once the drug-carrier material has been injected 
or otherwise implanted or taken orally into the body, the drug is released at a 
predetermined rate for some desired period of time. Controlled release technology is 
relatively new field and as a consequence, research in this field has been extremely 
fertile and has produced many discoveries. 
Non-immediate release delivery systems may be divided conveniently into 4 
categories, 
A. Delayed release 
B. Sustained release 
a) Controlled release 
b) Prolonged release 
C.   Site- specific release 
D.   Receptor release 
Delayed – release systems are those that use repetitive, intermittence dosing 
of a drug from one or more immediate release units incorporated into a single dosage 
forms to make delayed action. Example: Repeat- action tablets and capsules, enteric 
coated tablets where timed release achieved by a barrier coating. 
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Sustained- release systems includes any drug delivery system that achieves 
slow release of drug over an extended period of time. 
Controlled release systems are those systems which are successful 
maintaining constant drug levels in blood or target release (i.e.) release rate of drug 
occurs in controlled manner. 
Prolonged released systems only extends the duration of action and drug 
release that achieved by conventional drug delivery. 
Site specific and receptor release refers to targeting of drug directly to a 
certain biological location. In the case of site- specific release, the target is a certain 
organ or tissue, for receptor release, the target is the particular receptor for a drug 
within an organ or tissue. 
 
 
Fig: 1.1: Controlled drug release profile 
1.1.1.   Advantages of Novel Drug Delivery Systems: 
(Shoba Rani R Hire math., 2008) 
 Improved  therapy  by  increasing  the  duration  of  action  and  reduced  
side effects. 
 Increase t h e  patient  co m p l i an c e  t h r o u g h  d e c r e a s e d  d o s i n g  
f r eq uen cy  a n d  convenient routs of administration. 
Controlled Release Microspheres of Metoprolol tartrate                                                                            Introduction 
 
Adhiparasakthi College of Pharmacy, Melmaruvathur.         Page 4 
 
 Achieve targeting of drugs to a specific site to reduce unwanted side 
effects. 
1.2. CONTROLLED DRUG DELIVERY:  
One of essential issues of drug formulation is the controlled release of drugs, which 
can  improve  therapeutic  efficacy  by  offering  prolonged  in  vivo  action,  
controlled  blood concentration as well as tissue-targeted local release.  A possible 
approach to the biodegradable polymer microspheres. Controlled  drug  delivery  
occurs  when  a  polymer,  whether  natural  or  synthetic,  is judiciously combined 
with a drug or other active agent in such a way that the active agent is  released  from  
the  material  in  a  predesigned  manner.  The  release  of  the  active  agent may  be  
constant  or  cyclic  over a long  period,  or  it  may be  triggered  by the  environment 
or other  external events.  In any case,  the  purpose behind  controlling  the  drug  
delivery is to  achieve  more  effective  therapies  while  eliminating  the  potential  for  
both  under-  and overdosing.  The release patterns of drug from both formulations 
traditional and controlled are given in fig 1.2. 
 
Fig: 1.2: Drug levels in the blood with (a) traditional drug dosing and 
 (b) controlled- Delivery dosing. 
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Definition for controlled drug delivery system: 
                  Controlled release refers to the use of a delivery device with the 
objective of releasing the drug into the patient body at a predetermined rate, or at 
specific time or with specific release profiles. This could revolutionize the manner 
of medication effects and offer following advantages along with some disadvantages. 
 Advantages of control release dosage form: 
 Reducing the dosing frequency. 
 Reduced fluctuations in circulatory drug levels. 
 Avoidance of patient compliance. 
 Decreased side effects like reduced GI irritation. 
Disadvantages of control release dosage form: 
 High cost 
 Un predictable or poor in vivo-In-vitro correlation 
 Dose dumping 
 Reduced potential for dose adjustment 
 Poor systemic availability 
 Increased first pass clearance. 
Various  characteristics  of  drug  molecule  that  render  it  unsuitable  for  
controlled release dosing : 
 Narrow therapeutic index  
 Short/long elimination half life  
 Poor absorption  
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 Active absorption large doses  
 Low aqueous solubility  
 Extensive first pass metabolism  
 Incompatible pharmacological and   
 Circulation time course  
Biopharmaceutical aspects of regulatory requirement and new drug 
applications: 
 The controlled release formulation developed should aim to accomplish two important  
Objectives:  
 It  should allow  a  maximum  possible  percentage  of  the  dose in the 
formulation  to  be absorbed in controlled manner.  
 It should be capable of minimizing patient-to-patient variability.  
  Over the past  three decades,  considerable research  interest has arisen worldwide 
in  the  development  of  new  colloidal  drug  delivery  systems.  The ideal colloidal 
delivery system  could transport the associated  drug  to its  desired  site  of  action  and 
then  release  it at an optimum rate. The carrier itself  should be non-toxic and able to be 
degraded in vivo so  that  it  does  not  accumulate  indefinitely  in  the  tissues.  The 
colloidal  preparation  also needs  to  be  pharmaceutically  acceptable  with  regards  to  
stability  and  ease of administration. 
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PREREQUISITES FOR A DRUG TO BE SUITABLE FOR DESIGN OF ORAL 
CONTROLLED RELEASE DOSAGE FORM
    
(Bandyopadhyay A .K., 2008) 
Some characteristics make a drug more suitable for extended release dosing, such as 
1. Elimination half-life between 2 to 8 hours. 
2. Broader therapeutic index. 
3. Moderate unit dose. 
4. Significant extent of absorption in GIT. 
5. Optimum solubility characteristics. 
6. Minimal first-pass clearance 
 
 
FACTORS INFLUENCING THE DESIGN AND PERFORMANCE OF 
CONTROLLED RELEASE PRODUCTS:                                        
 
Oral drug delivery is the most widely utilized route of administration among 
all the routes that have been explored for the systemic delivery of drugs via various 
pharmaceutical products in different dosage forms. Irrespective of their mode of 
delivery (immediate, sustained or controlled release) and the design of dosage forms 
(either solid or liquid) they must be developed within the intrinsic characteristics of 
GIT physiology. Therefore a fundamental understanding of pharmacokinetics, 
pharmacodynamics and formulation design is essential to achieve a systematic 
approach to the successful development of an oral pharmaceutical dosage form. A 
number of variables such as drug properties, route of delivery, target sites, duration of 
therapy, the disease state and patient variables must be considered. The formulation 
and performance of sustained release products are greatly influenced by the 
physicochemical and biological properties of drug. 
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1.3. PRINCIPLE BEHIND SR/CR DRUG RELEASE: (Bankar G.S and Rhodes 
C.T., 2009; Brahmankar D.M and Jaiswal S.B., 2009; Robinson J.R and Lee V.H.L., 
2005) 
Dissolution and diffusion controlled systems have classically been of primary 
importance in oral delivery of medication because of their relative ease of production 
and cost compared with other methods of sustained or controlled delivery. Most of 
these systems are solids, although a few liquids and suspension have been recently 
introduced. 
The classification of such systems is as follows: 
1. Diffusion controlled systems. 
2. Dissolution controlled systems. 
3. Dissolution and Diffusion controlled systems. 
4. Osmotically controlled systems. 
5. Ion exchange systems. 
 
1. Diffusion Controlled  Systems 
Diffusion systems are characterized by the release rate being dependent on its 
diffusion through an inert membrane barrier. Usually this barrier is an insoluble 
polymer. In general two types of sub classes of diffusion systems are recognized they 
are 
a. Reservoir devices. 
b. Matrix devices. 
a. Reservoir devices 
Reservoir devices are characterized by a core drug reservoir surrounded by a 
polymeric membrane. 
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Figure 1.3: Systematic representation of diffusion controlled drug 
 release matrix system. 
 
 
Figure 1.3 Schematic representation of reservoir diffusion device Cm (o), and 
Cm (d) represent concentration of drug inside surfaces of membrane and C (o) & C 
(d) represents concentration in adjacent regions. 
If it is assumed that the drug on the both side of membrane is in equilibrium 
with its respective membrane surface which in equilibrium between the membrane 
surfaces and their bathing solutions as shown in Figure 1.2 
Therefore the concentration just inside the membrane surface can be related to 
the concentration in the adjacent region by following expression. 
K = Cm (o) /C(d)      at  X = o                                   (2) 
K = Cm (d) / C(d)     at  X = d                                   (3) 
Where K = partition coefficient. If we consider K & D are constants 
then equation (1) becomes, 
J = D K C/d                                                (4) 
 Where c is the concentration difference across the membrane and d 
is path length of diffusion. The simplest system to consider is that of slab, where drug 
release is from only one surface as shown Figure 1.2  in this case equation (4) 
becomes 
            dMt/ dt  =    ADK C/ d                                     (5) 
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The process of diffusion is generally described by Ficks equation, 
                   J         =     -D dc/dx 
Where,   J         -- Flux (amount/ area –time) 
D     -- Diffusion co-efficient of drug in the membrane (area / time)   
Dc/dx  -- rate of exchange in concentration C, with respect to a 
distance X         in the membrane. 
Advantages 
1. Zero order delivery is possible. 
2. Release rate variable with polymer type. 
Disadvantages 
1. Potential toxicity if system fails. 
2. System must be physically removed from implant sites. 
3. Difficult to deliver high molecular weight compounds. 
4. Generally increased cost per dosage units. 
b. Matrix Devices 
It contains of drug dispersed homogeneously throughout a polymer matrix. In 
this model, drug in the outside layer exposed to bath solution is dissolved first and 
then diffuses out of the matrix. The following equation describe the rate of release of 
drug dispersed in an inert matrix system have been derived by Higuchi. 
                         Dm/dh  = Codh – Cs/2. 
Where,   dm      = Change in the amount of drug released per unit area. 
                         dh      = Change in the thickness of the zone of matrix that have 
been depleted of drug. 
                    Co      =  Total amount of drug in unit volume of matrix. 
                    Cs      = Saturated concentration of drug within the matrix. 
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Figure1. 4: Release of drug dispersed in an inert matrix system. 
Advantages 
1. Can deliver high molecular weight compounds. 
2. Easier to produce than reservoir devices. 
Disadvantages 
1. Removal of remaining matrix is necessary for implanted systems. 
2. Cannot obtain zero order release. 
Diffusion Rate Modifications 
Modification of the following will change the rate of diffusion 
(a) Thickness of the separating layer 
(b) Porosity 
(c) Partition coefficient 
(d) Modification of the diffusion co-efficient. 
(e) Modification of efficient molecular size. 
(f) Modification of viscosity. 
(g) Modification of concentration. 
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2. Dissolution-controlled Systems 
Drug with a slow dissolution rate will demonstrate sustaining properties, since 
the release of the drug will be limited by rate of dissolution. This being the case, SR 
preparations of drugs could be made by decreasing their dissolution rate. This 
includes preparing appropriate salts or derivatives, coating the drug with a slowly 
dissolving material, or incorporating it into a tablet with a slowly dissolving carrier. 
The dissolution process at steady state, is described by Noyes-Whitney 
equation, 
dc/dt = KDA(Cs-C) = D/h A(Cs-C) 
Where, 
dc/dt  = Dissolution rate. 
KD = Diffusion co-efficient 
A         = surface area of the dissolving solid 
Cs = Saturation solubility of the solid. 
C = Concentration of solute in bulk solution. 
H = Thickness of diffusion layer. 
Principles of dissolution rate modification 
The following are may affect dissolution rate modification of 
(a) Solubility, 
(b) Specific area, 
(c) Particle shape and surface structure, 
(d) Dissolution conditions (contact of solid particles with the 
Solvent) and 
(e) Crystallographic modification. 
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3. Dissolution and Diffusion - Controlled release system 
Normally, therapeutic systems will never be dependent on dissolution only or 
diffusion only. In practice, the dominant mechanism for release will over shadow 
other processes enough to allow classification as either dissolution rate limited or 
diffusion controlled. 
The mechanism of release from simple erodible slabs, cylinders and spheres 
has been described by Hopenberg are described as 
   Mt/M = 1 - (1- Kot/Co a)
n 
Where,   n = 2 for cylinder and 
n = 1 for a slab. 
a = Radius of sphere or cylinder or half height of a slab. 
Mt  = Mass of drug release at time t 
M = Mass released infinite time. 
Advantages 
1. Easier to produce than reservoir devices. 
2. Can deliver high molecular weight compounds. 
3. Removal from implant sites is not necessary. 
Disadvantages 
1. Difficult to control kinetics owning to multiple process of release. 
2. Potential toxicity of degraded polymer must be considered. 
4. Osmotically controlled systems 
This device is fabricated as tablet that contains water soluble osmotically active 
drug, of that was blended with osmotically active diluents by coating the tablet with a 
cellulose triacetate barrier which functions as a semi permeable membrane. A laser is 
used to form a precision orifice in the barrier, through which the drug is released due 
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to development of osmotic pressure difference across the membrane, when this was 
kept in water. 
 
Figure 1.5: Osmotically controlled release systems. 
5.  Ion Exchange Systems 
These are salts of cationic or anionic exchange resins or insoluble complexes 
in which drug release results from exchange of bound drug ions that are normally 
present in GI fluids. 
 
1.4.MICROSPHERES:                                                                                                         
(shobharani., 2008; Kedar Prasad Meena and Danji J.S., et al., 2011) 
 Microspheres are solid, approximately spherical particles ranging 1-1000µm 
in size. They are made up of polymeric substances, in which the drug is dispersed 
throughout the microsphere matrix. The substances used in the formulation are 
biodegradable synthetic polymers and natural products. The natural polymers of 
choice are albumin and gelatin, the synthetic ones being polylactic acid and 
polyglycolic acid. The polymers used to manufacture microspheres are chosen 
according to their solubility, stability profile, process, safety and economic suitability. 
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                                         Fig 1.6: Microspheres 
Advantages of microsphere delivery system: 
•   Protection of unstable, sensitive materials from their environments prior to use. 
•   Better process ability (improving solubility, dispersibility, flowability) 
•   Self-life enhancement by preventing degradative reactions. 
•   Safe and convenient handling of toxic materials. 
•   Masking of odor or taste. 
•   Enzyme and microorganism immobilization. 
•   Controlled and targeted drug delivery. 
•   Handling liquids as solids. 
•   To improve bioavailability 
•   To improve the stability 
•   Limiting fluctuation within therapeutic range 
Applications of microspheres 
Some of the applications of microspheres can be described in detail as given 
below  
1. Prolonged release dosage forms. The microsphere drug can be administered, 
as microsphere is perhaps most useful for the preparation of tablets, capsules 
or parenteral dosage forms. 
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3. Microsphere can be used to prepare enteric coated dosage forms, so that the 
medicament will be selectively absorbed in the intestine rather than the 
stomach. 
4. It can be used to mask the taste of bitter drugs. 
5. From the mechanical point of view, microsphere has been used to aid in the 
addition of oily medicines to tablet dosage forms. This has been used to 
overcome problems inherent in producing tablets from otherwise tacky 
granulations. This was accomplished through improved flow properties. For 
example, the non-flowable multicomponent solid mixture of niacin, 
riboflavin, and thiamine hydrochloride and iron phosphate may be 
encapsulated and made directly into tablets. 
6. It has been used to protect drugs from environmental hazards such as 
humidity, light, oxygen or heat. Microsphere does not yet provide a perfect 
barrier for materials, which degrade in the presence of oxygen, moisture or 
heat, however a great degree of protection against these elements can be 
provided. For example, vitamin A and K have been shown to be protected 
from moisture and oxygen through microsphere. 
7. Microsphere can be used to decrease the volatility. An encapsulated volatile 
substance can be stored for longer times without substantial evaporation. 
8. Microsphere has also been used to decrease potential danger of handling of 
toxic or noxious substances. The toxicity occurred due to handling of 
fumigants, herbicides, insecticides and pesticides have been advantageously 
decreased after microencapsulation. 
9. The hygroscopic properties of many core materials may be reduced by 
microsphere. 
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10. Many drugs have been microsphere to reduce gastric irritation. 
11. Microsphere method has also been proposed to prepare intrauterine 
contraceptive device. 
 
1.5. Classification of polymers used for preparation of microspheres                     
(Vyas S.P., 2002) 
A number of different substances both biodegradable as well as non-biodegradable 
have been investigated for the preparation of microspheres. These materials include 
the polymers of natural and synthetic origin and also modified natural substances. 
Some of the polymers used in the preparation of the microspheres are classified and 
listed below. 
 Types of polymers used in preparation of microspheres    
Classification:  
1] Synthetic polymer  
A] Non biodegradable:  
 Acrolein  
 Glycid yl methacrylate  
 Epoxy polymer  
 PMMA  
B] Biodegradable:  
 Poly anhydrides  
 Lactides and glycolides and their copolymer.  
 Poly alkyl cyno acrylates  
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2] Natural Materials  
A] Proteins  
 Albumins  
 Gelatins  
 Collagens  
B] Carbohydrates  
 Chitosan  
 Carrageenan  
 Starch 
 C] Chemically modified carbohydrates 
 Poly acryl starch 
 Poly acryl dextran 
 
1.6. TYPES OF MICROSPHERES  
Bio adhesive microspheres:  
Adhesion  can  be  defined  as sticking  of  drug  to  the  membrane  by  using  the  
sticking  property of  the  water  soluble  polymers.  Adhesion  of  drug  delivery  device  
to   the  mucosal  membrane such  as  buccal ,   ocular ,  rectal,  nasal  etc  can  be  
termed  as  bio  adhesion . These kinds of microspheres exhibit a pro longed residence 
time at the site of application and causes intimate contact with the absorption site and 
produces better therapeutic action. 
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Magnetic microspheres  
This  kind  of  delivery  system  is  very  much  important which  localizes the  drug  
to  the  disease site.  In  this  larger  amount  of  freely  circulating  drug  can  be  
Replaced  by  smaller  amount  of magnetically targeted  drug. Magnetic  carriers receive  
magnetic  responses  to  a magnetic field  from  incorporated  materials  that  are  used  
for  magnetic  microspheres  are  chitosan,  dextran etc. The  different  type  are  
Therapeutic  magnetic  microspheres:  Are  used  to  deliver chemo therapeutic agent to  
liver  tumor.  Drugs like proteins and peptides  can  also be  targeted thro ugh  this 
system.6  Diagnostic  microspheres: Can  be used  for  imaging liver  metastases and  
also  can  be used to distinguish  bowel lo ops  from other abdominal  structures  by  
forming  nano  size particles supra magnetic iron  oxides.  
 
Floating micro spheres: 
In  floating  types  the  bulk  density  is  less  than  the  gastric  flu id  and  so  remains  
buoyant  in stomach  without  affecting  gastric  emptying  rate.  The drug is released 
slowly at the desired  rate,  if  the system  is  floating o n  gastric  content and  increases 
gastric residence and  increases  fluctuation in  plasma  concentration.  Moreover it also 
reduces chances of striking and dose dumping.  One  another  way  it  produces  
prolonged  therapeutic  effect  and  therefore  reduces dosing frequencies. Drug 
(ketoprofen) given through this form.  
 
Polymeric microspheres:  
         The  different  types  of  polymeric  microspheres  can  be  classified  as  follows 
and  they  are Bio degradable polymeric microspheres and Synthetic polymeric 
microspheres. 
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 Biodegradable polymeric microspheres:  
     Natural  polymers  such  as  starch  are  used  with  the  concept  that  they  are  bio 
degradable, Biocompatible, and also bio adhesive in nature.  Biodegradable polymers 
prolongs the residence  time when  contact  with  mucous  membrane  due  to  its  high  
degree  o f  swelling  property with  aqueous  medium  ,  results  gel  formation.  The rate 
and extent of drug release is controlled  by  concentration  of  polymer  and  the  release  
pattern  in  a  sustained  manner.  The main  drawback  is,   in  clinical  use  drug  loading  
efficiency  of  biodegradable  microspheres  is complex and  is  difficult  to  control  the  
drug  release.  However they provide wide range of application in microsphere based 
treatment. 
 
Synthetic polymeric microspheres:  
The  interest  of  synthetic  polymeric  microspheres  are  widely  used  in  clinical  
application, More over that also used as bulking agent, fillers, embolic part icles, 
drug delivery vehicles etc and  proved  to  be  safe  and  bio compatible. But the 
main disadvantage of these kinds of microspheres, are tend to migrate away from 
injection site and lead to potential risk, embolism and further organ damage. 
 
Radioactive microspheres: 
 Radio emobolisation therapy microspheres sized 10-30nm is of larger than 
capillaries and gets tapped in first capillary bed when they come across. They are 
injected to the arteries that lead to tumour of interest.  So all these conditions 
radioactive microspheres deliver high radiation dose to the targeted areas without 
damaging the normal surrounding tissues. 
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Prerequisites for ideal microsphere carriers: 
            The polymer utilized for the preparation of microspheres should ideally fulfill 
the following prerequisites 
 Longer duration of action 
 Control of content release 
 Increase of therapeutic efficacy 
 Protection of drug 
 Reduction of toxicity 
 Biocompatibility 
 Sterilizability 
 Relative stability 
 Water solubility or dispersability 
 Bioresorbability 
 Targetability 
 Polyvalent 
 
1.7. PREPARATION METHOD OF MICROSPHERE                   
                                                         (Kedar Prasad Meena and Danji J.S., et al., 2011) 
Preparation of microspheres should satisfy certain criteria 
 The ability to incorporate reasonably high concentrations of the drug. 
 Stability of the preparation after synthesis with a clinically acceptable shelf 
life. 
 Controlled particle size and dispersability in aqueous vehicles for injection. 
 Release of active reagent with a good control over a wide time scale. 
 Biocompatibility with a controllable biodegradability. 
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METHODS USED FOR PREPARATION OF MICROSPHERES:  
 
1. Protein gelation technique 
2. Emulsion polymerization technique 
3. Solvent evaporation technique 
4. Soncation technique 
5. Spray drying technique 
6. Emulsion-heat stabilization technique 
7. Spherical crystallization technique 
8. Spray congealing 
9. Phase separation coaservation method 
10. Polymerization technique 
1. Protein gelation technique 
Dissolve egg albumin in distilled 
water 
↓ 
Add drop wise into olive oil to make 
emulsion 
↓ 
From the dropping funnel, emulsion was added drop wise into preheated 
Olive oil (125±5
0
C) 
                         ↓Stir at 1500 rpm 
After heat sterilization for 10 minutes the preparation was cooled to 25
0
C 
          ↓Centrifuge at 2500 rpm, decant the supernatant 
Wash the microspheres with liquid paraffin and twice with ether to obtain a free  
Flowing and discreet product 
↓ 
 Suspended the microspheres in anhydrous ether, stir at 4
0
C in an airtight container 
 
Figure 1.7: Preparation of microspheres by Protein gelation technique. 
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2. Emulsion polymerization technique 
 
Take 100ml of light paraffin oil in glass beaker , mix with 
0.4% w/v span 60 
                                                        ↓Stir and heat at 700C until complete solubilisation 
Cool the mixture at room temperature 
                                                         ↓ 
Drop wise add 10ml of egg albumin aqueous solution of different drug to 
polymer ratio (1:1, 1:5, 1:2) using a 22-gauge hypodermic syringe into external phase 
                                              ↓ Stir light paraffin at 600 rpm for 10 minutes 
A w/o emulsion was formed 
                                              ↓Raise the temperature of oil bath to 950C, 
                                                     stir until microspheres completely dehydrate 
Microspheres thus obtained were decanted, washed 6 times with 20ml 
petroleum ether for 2 minutes at 700 rpm 
                                                         ↓ finally wash 3 times with 60 oz of distilled                  
                                                           water for 2 minutes at 700 rpm, dry at room temp    
                                                           for 24 hour 
After drying, a fine yellow free flowing powders of microsphere were 
obtained that was stored in desiccators at room temperature. 
 
Figure 1.8: Preparation of microspheres by emulsion polymerization      
                    technique. 
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Figure 1.9: Microsphere preparation by emulsion method 
3. Solvent evaporation technique 
A core material to be microencapsulated is dissolved or dispersed in the 
coating polymer solution. With agitation the core material mixture is dispersed in the 
liquid manufacturing vehicle phase to obtain the appropriate size microsphere. The 
mixture is then heated if necessary to evaporate the solvent. The solvent Evaporation 
technique to produce microspheres is applicable to wide variety of core materials. The 
core materials may be either water soluble or water insoluble materials. Solvent 
evaporation involves the formation of an emulsion between polymer solution and an 
immiscible continuous phase whether aqueous (o/w) or non-aqueous.  
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Figure 1.10: Basic steps of microsphere by solvent evaporation method 
 
4. Sonication technique: 
As the technique name itself is self explanatory, it just involves a simple 
sonication for certain period of time till a desired size of microspheres are obtained. 
The polymer solution of desired concentration is taken which is sonicated. To this add 
the drug which will then form intrachain cross-link with cysteine residues of polymer 
chains. Prepared a stable preparation of air filled human polymer microspheres 
(Albunex) by sonication technique. The microspheres ranged in size from 1-10m with 
99% of particles smaller than 10 m. The mean size was 5 m, which is small enough to 
pass freely through the pulmonary capillary circulation. 
 
5.  Spray drying technique: 
In Spray Drying the polymer is first dissolved in a suitable volatile organic 
solvent such as dichloromethane, Acetone, etc. The drug in the solid form is then 
dispersed in the polymer solution under high-speed homogenization. This dispersion 
is then atomized in a stream of hot air. The atomization leads to the formation of the 
small droplets or the fine mist from which the solvent evaporate instantaneously 
leading the formation of the microspheres in a size range 1-100m.  
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Figure 1.11: Main process stages involved in spray drying process. 
 
 
 
 
 
 
Figure 1.12: Formation of product in spray drying. 
 
Principle 
There are three fundamental steps involved in spray drying 
1) Atomization of a liquid feed into fine droplets. 
2) Mixing of these spray droplets with a heated gas stream, allowing the liquid to 
evaporate and leave dried solids. 
3) Dried powder is separated from the gas stream and collected. Spray drying involves 
the atomization of a liquid feedstock into a spray of droplets and contacting the 
droplets with hot air in a drying chamber. 
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The sprays are produces by either rotary (wheel) or nozzle atomizers. 
Evaporation of moisture from the droplets and formation of dry particles proceed 
under controlled temperature and airflow conditions. Powder is discharged 
continuously from the drying chamber. Operating conditions and dryer design are 
selected according to the drying characteristics of the product and powder 
specification. 
6. Emulsification-heat stabilization technique 
5% solution of BSA containing 0.1% Tween80 was made, to which 4% drug 
was added and used as the aqueous phase. The oil phase composed of 30 ml maize oil 
and 10 ml petroleum ether with 1% Span 80 as emulsifier were mixed together and 
allowed to stir for 10 min at 1000 rpm. The aqueous phase was added drop wise to the 
oil phase and stirred on a magnet stirrer at 1000 rpm for 30 min to form the initial 
emulsion. This emulsion was then added to 40 ml of maize oil preheated to 120° C 
and stirred at 1000 rpm for 15 min to allow the formation and solidification of 
microspheres. The microsphere suspension was centrifuged at 3500 rpm for 30 min 
and the settled microspheres were washed three times with ether to remove traces of 
oil on microsphere surfaces. The microspheres were vacuum dried in desiccators 
overnight and stored were vacuum dried in a desiccators overnight and stored at 4°C 
in dark. The microspheres had mean diameters between 1-25 m of which more than 
50 percent were below 5 m.  
7. Spherical crystallization technique. 
Development and characterization of sustained release microspheres by 
solvent diffusion  method. The microspheres were prepared using the emulsion 
solvent diffusion  method of the spherical crystallization technique. Drug and polymer 
were dissolved completely in the acetone–dichloromethane mixture. Then Aerosil was 
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suspended uniformly in the drug– polymer solution under vigorous agitation. The 
resultant drug–polymer– Aerosil suspension was poured into the distilled water (150 
ml) containing 0.08% of SDS (i.e. poor solvent) under a moderate agitation   (450–
750rpm) and thermally controlled at 0–38°C. The suspension was finely dispersed 
into emulsion droplets immediately under agitation, and the drug and polymers co 
precipitated in the emulsion droplets. After agitating the system for 20 min, 150 ml of 
poor solvent was added slowly to promote the diffusion of the good solvent from 
emulsion droplets into poor solvent resulting in enhancement of the solidification of 
emulsion droplets.  
8.  Spray congealing 
The polymer is first dissolved in a suitable volatile organic solvent such as 
dichloromethane, acetone, etc. The drug in the solid form is then dispersed in the 
polymer solution under high speed homogenization. This dispersion is then atomized 
in a stream of cold air. The atomization leads to the formation of the small droplets or 
the fine mist from which the solvent evaporates instantaneously leading the formation 
of the microspheres in a size range 1-100 m. 
9. Phase separation coacervation technique 
This process is based on the principle of decreasing the solubility of the 
polymer in organic phase to affect the formation of polymer rich phase called the 
coacervates. In this method, the drug particles are dispersed in a solution of the 
polymer and an incompatible polymer is added to the system which makes first 
polymer to phase separate and engulf the drug particles. Addition of non-solvent 
results in the solidification of polymer. Poly lactic acid (PLA) microspheres have 
been prepared by this method by using butadiene as incompatible polymer. The 
process variables are very important since the rate of achieving the coacervates 
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determines the distribution of the polymer film, the particle size and agglomeration of 
the formed particles. The agglomeration must be avoided by stirring the suspension 
using a suitable speed stirrer since as the process of microspheres formation begins 
the formed polymerize globules start to stick and form the agglomerates. Therefore 
the process variables are critical as they control the kinetic of the formed particles 
since there is no defined state of equilibrium attainment 
10. Polymerization techniques 
The polymerization techniques conventionally used for the preparation of the 
microspheres are mainly classified as:  
I. Normal polymerization 
II. Interfacial polymerization. Both are carried out in liquid phase. 
•   Normal polymerization 
It is carried out using different techniques as bulk, suspension, precipitation, 
emulsion and micellar polymerization processes. In bulk, a monomer or a mixture of 
monomers along with the initiator or catalyst is usually heated to initiate 
polymerization. Polymer so obtained may be moulded  as microspheres. Drug loading 
may be done during the process of polymerization. Suspension polymerization also 
referred as bead or pearl polymerization. Here it is carried out by heating the 
monomer or mixture of monomers as droplets dispersion in a continuous aqueous 
phase. The droplets may also contain an initiator and other additives. Emulsion 
polymerization differs from suspension polymerization as due to the presence initiator 
in the aqueous phase, which later on diffuses to the surface of micelles. Bulk 
polymerization has an advantage of formation of pure polymers. 
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•   Interfacial polymerization 
It involves the reaction of various monomers at the interface between the two 
immiscible liquid phases to form a film of polymer that essentially envelops the 
dispersed phase 
 
Loading of drug:           (vyas s.p., 2002)
 The active components are loaded over the microspheres principally using two 
methods. i.e. during the preparation of the microspheres or after the formulation of the 
microsphere by incubating them with the drug/protein. The active component can be 
loaded by means of the physical entrapment, chemical linkage and surface absorption. 
The entrapment largely depends on the method of preparation and nature of the drug 
or polymer.  
Maximum loading can be achieved by incorporating the drug during the time 
of preparation but it may get affected by many other process variables such as method 
of preparation, presence of additives, heat of polymerization, agitation intensity, etc. 
The loading is carried out in pre-formed microspheres by incubating them 
with high concentration of the drug in a suitable solvent. The drug in these 
microspheres loaded via penetration or diffusion of the drug through the pores in the 
microspheres as well as adsorption on the surface. The drugs and protein can also be 
incorporated by physical or chemical linkage. The absorption of the drug/proteins 
depends on the nature of the polymers. 
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1.8. DRUG RELEASE KINETICS 
Release of the active constituent is an important consideration in case of 
microspheres. Many theoretically possible mechanisms may be considered for the 
release of drug from the microspheres. 
1. Liberation due to polymer erosion or degradation, 
2. Self diffusion through the pore, 
3. Release from the surface of the polymer, 
4. Pulsed delivery initiated by the application of an oscillating or sonic field. 
                             
           Figure 1.13: Possible drug release mechanisms for polymeric drug delivery 
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FACTORS INFLUENCING PROPERTIES OF MICROSPHERES. :           
(Kedar Prasad Meena and Danji J.S.,et al.,  2011) 
 
Figure 1.14: Factors effecting properties of microspheres 
(A) Dispersed phase 
1. Polymers commonly used to form microspheres 
2. Choice of solvent 
(1) Should be able to dissolve the chosen polymer; 
(2) Poorly soluble in the continuous phase; 
(3) High volatility and a low boiling point; 
(4) Low toxicity. 
(5) Alternative components (dispersed phase) 
(a) Co-solvent:- organic solvents miscible with water such as methanol   and ethanol. 
(b) Porosity generator:- increases the degradation rate of polymer and improves drug 
release rate.  E.g. Incorporating sephadex (cross-linked dextran gel) into insulin–pla 
microspheres significantly increases microsphere porosity. 
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(B) Continuous phase 
(a) Surfactant:- 
•   It reduces the surface tension of continuous phase. 
•   Avoids the coalescence and agglomeration of drops. 
•   Stabilizes the emulsion. 
•   Widely used stabilizers include: 
i. Non-ionic: partially hydrolyzed poly vinyl alcohol, methylcellulose, tween, span 
ii. anionic: sodium dodecyl sulphate (sds), sodium lauryl sulphate. 
iii. cationic: cetyltrimethyl ammonium bromide (ctab). 
(b) Alternative component:- 
•   Antifoaming agent - foaming problem will disturb the formation of microspheres. 
•   Anti-foams of silicon and non-silicon constituents are used. 
(C) Impact of parameters and operating conditions on the properties of microspheres. 
Technology limitations in preparing microspheres 
 Residual solvents 
 Stability 
 Non availability of degradable, synthetic polymers 
 Encapsulation efficiency 
 Limitation of manufacturing process 
 Sterilization 
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1.9. HYPERTENSION     (http://www.hypertension.com) 
High blood pressure, termed "hypertension," is a condition that afflicts almost 
1 billion people worldwide and is a leading cause of morbidity and mortality. More 
than 20% of Americans are hypertensive, and one-third of these Americans are not 
even aware they are hypertensive. Therefore, this disease is sometimes called the 
"silent killer." This disease is usually asymptomatic until the damaging effects of 
hypertension (such as stroke, myocardial infarction, renal dysfunction, visual 
problems, etc.) are observed. Hypertension is a major risk factor for coronary artery 
disease, myocardial infarction ("heart attacks") and stroke. 
Definition of Hypertension: 
Hypertensive is defined as an abnormal elevation in diastolic pressure and/or 
systolic pressure; mean arterial pressure is also elevated in hypertension, but it is not 
usually measured in people. In past years, the diastolic value was emphasized in 
assessing hypertension.  However, elevations in systolic pressure ("systolic 
hypertension") are also associated with increased incidence of coronary and 
cerebrovascular disease (e.g., stroke). 
        Table: 1.1 Classification of hypertension   
Classification 
Systolic 
(mmHg) 
Diastolic 
(mmHg) 
Normal <120 <80 
Pre hypertension 120-139 80-89 
Stage 1 140-159 90-99 
Stage 2 >160 >100 
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Types of High Blood Pressure: 
       High blood pressure (also called hypertension) based on cause and characteristics. 
 Essential Hypertension 
 Isolated Systolic Hypertension 
 Secondary Hypertension  
 White-Coat Hypertension 
 Labile Hypertension 
 Malignant Hypertension 
 Hypertension During Pregnancy 
Essential Hypertension 
About 90 to 95 percent of people with high blood pressure have essential 
hypertension or primary hypertension. This means the condition has no identifiable 
medical cause as its source. Essential hypertension is often inherited. Elevated blood 
pressure usually begins to appear between age 30 and 50, but can begin at older ages.  
Without a definite understanding of what causes essential hypertension, 
doctors often explain it as a malfunction of one or more parts of the blood-pressure 
regulatory system. Different factors increase blood pressure in different people. That's 
why a treatment that lowers blood pressure in one person does not always work in 
another. For example, a person who is "salt sensitive" usually can control his or her 
blood pressure with a low-salt (sodium) diet alone, while another person may find salt 
intake has little or no influence on blood pressure. 
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Isolated Systolic Hypertension 
As people age, their arteries tend to lose elasticity and become less able to 
accommodate blood surges, leading to hardening of the arteries (arteriosclerosis). 
Hardening of the arteries can elevate systolic blood pressure (the top number of your 
blood pressure), while diastolic pressure (the bottom number) stays in the normal 
range. This condition, called isolated systolic hypertension, is the most common form 
of high blood pressure in the elderly. 
The Framingham Heart Study, which has tracked the health of participants 
since the late 1940s, found that 65 percent to 75 percent of people over age 65 with 
elevated blood pressure had isolated systolic hypertension. 
In the past, doctors considered this type of high blood pressure to be normal in 
elderly patients, so normal that it wasn't even treated. However, a 1991 study, Systolic 
Hypertension in the Elderly Program (SHEP), provided strong evidence to the 
contrary. SHEP tracked 4,736 patients with isolated systolic hypertension over five 
years. Half the participants used drugs to lower their blood pressure, while the other 
half received a placebo (an inactive pill). The group taking medication had 
significantly fewer strokes and heart attacks than the placebo group. The SHEP study 
has spurred doctors to treat isolated systolic hypertension in older patients more 
aggressively. 
Secondary Hypertension  
Some medical conditions and medications can cause high blood pressures. 
This is called secondary hypertension, because high blood pressure is the second thing 
to develop, after the initial medical condition. Often, if the medical problem can be 
identified and treated, the high blood pressure will come back down to a normal level. 
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Your doctor may suspect secondary hypertension if your blood pressure if very 
difficult to control with medicines.  
White-Coat Hypertension 
Anxiety can raise blood pressure. That's why some people who have a normal 
blood pressure at home find that their blood pressure is high when they see a doctor. 
This phenomenon is called "white-coat hypertension."  
If you or your doctor thinks you have "white-coat hypertension," you can use a 
home blood-pressure machine to check your blood pressure periodically over the 
course of a week or two. 
Labile Hypertension: 
Labile hypertension is blood pressure that fluctuates abruptly and repeatedly, 
often causing symptoms such as headache or ringing in the ears. People sudden 
increase in your blood pressure. With labile hypertension often react to emotional 
stress with an increase in blood pressure. Frequently, traditional blood-pressure 
medicines have little effect. Some people with labile hypertension require anti-anxiety 
medications in order to gain control of their blood pressure. 
People who are habitually affected by stress — whether from losing a job, 
feeling pressure at work or simply getting stuck in traffic — may develop high blood 
pressure that could inflict some of the same damage as full-time hypertension. 
Malignant Hypertension 
Though rare, malignant hypertension is the most threatening form of high 
blood pressure. It's marked by an unusually sudden rise in blood pressure to 
dangerous levels. Diastolic pressure often reaches 130 or higher. However, malignant 
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hypertension may also occur at lower, less alarming levels, if the rise is particularly 
sudden. Unlike other kinds of high blood pressure, malignant hypertension is usually 
accompanied by dramatic symptoms such as severe headache, shortness of breath, 
chest pain, nausea and vomiting, blurred vision, or even blindness, seizures and loss 
of consciousness. 
Malignant hypertension is an emergency. Anyone with malignant 
hypertension must be hospitalized immediately. It places people at immediate risk for 
heart attack, stroke, heart failure, permanent kidney damage, bleeding into the brain 
(hemorrhagic stroke) and brain swelling. 
Malignant hypertension develops in less than 1 percent of people who already 
have high blood pressure. Rarely, the appearance of malignant hypertension is the 
first sign that a person has high blood pressure. The cause of this condition is usually 
unknown, but occasionally it can be a reaction of your body to a drug of abuse, like 
cocaine, or a reaction to stopping a blood-pressure medicine. 
Hypertension during Pregnancy: 
High blood pressure occurs in 6  to 8 percent of pregnancies, and in most of 
these cases, it is diagnosed during a first pregnancy. Pregnancy can cause high blood 
pressure due to hormonal changes or from a serious complication of pregnancy known 
as preeclampsia, a condition that causes tightening of arteries throughout the mother’s 
body and placenta, as well as unpredictable blood clotting. 
High blood pressure in the first half of a pregnancy (the first 20 weeks) is called 
chronic hypertension in pregnancy. High blood pressure in the second half of 
pregnancy (weeks 20 through 40) could be any of the following: 
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1. Chronic hypertension: in pregnancy is high blood pressure caused by a 
condition unrelated to pregnancy (such as essential hypertension or secondary 
hypertension) that begins or continues during pregnancy. The rise in blood 
pressure may have predated the pregnancy by months or years. However, this 
rise is first noticed during pregnancy, when a woman who has not regularly 
visited a doctor gets prenatal care. Chronic hypertension in pregnancy 
continues after the baby is delivered. Women with chronic hypertension in 
pregnancy are at increased risk for developing preeclampsia. 
2. Gestational hypertension (or pregnancy-induced hypertension) is high blood 
pressure that results from the effects of the hormone estrogen. Blood pressure 
returns to normal within 12 weeks after the baby is delivered.  
3. Preeclampsia (or toxemia of pregnancy) causes tightening of arteries 
throughout the mother’s body and placenta, as well as unpredictable blood 
clotting. It not only creates high blood pressure but also causes fluid retention 
that leads to swelling of the feet and legs (and sometimes the hands and face), 
and protein in the urine. Preeclampsia can progress to cause neurological 
symptoms including seizures. Preeclampsia requires very close attention from 
your doctor and frequently requires the early delivery of the baby in order to 
keep both mother and baby safe from harm. 
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Sometimes it's not possible to know what causes blood pressure to rise during 
pregnancy until the pregnancy is over. Protein in the urine any time during pregnancy 
or in the first 12 weeks after delivery confirms preeclampsia. If high blood pressure 
goes away within 12 weeks of delivery, and there was never significant protein in the 
urine, the cause can be diagnosed as gestational hypertension. If high blood pressure 
does not go away after delivery, chronic hypertension is the culprit. It is even possible 
to have two causes of high blood pressure during pregnancy. For example, a woman 
with chronic hypertension may develop preeclampsia in the second half of her 
pregnancy.  
 Etiology & Classification: 
 Primary (Essential) Hypertension  
  1. Sympathetic nervous system hyperactivity  
  2.Abnormal cardiovascular development  
  3.Renin- angiotensin system activity  
  4.Defect in natriuresis  
  5.Intracellular sodium and calcium  
  6.Exacerbating factors  
 Secondary Hypertension  
  1.Renal disease  
  2.Genetic causes  
  3.Renal vascular hypertension  
  4. Primary hyperaldosteronism  
  5 Cushing's syndrome  
  6. Pheochromocytoma  
  7. Coarctation of the aorta  
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  8. Hypertension associated with pregnancy  
  9. Estrogen use  
  10.Other causes of secondary hypertension  
Signs and symptoms of  hypertension: 
Signs and symptoms of pulmonary hypertension (PH) may include: 
 Shortness of breath during routine activity, such as climbing two flights of 
stairs 
 Tiredness 
 Chest pain 
 A racing heartbeat 
 Pain on the upper right side of the abdomen 
 Decreased appetite 
As PH worsens, you may find it hard to do any physical activities. At this point, other 
signs and symptoms may include: 
 Feeling light-headed, especially during physical activity 
 Fainting at times 
 Swelling in your legs and ankles 
 
 Treatment of Hypertension: 
Most people with hypertension are treated with antihypertensive medications. In most 
forms of hypertension, the hypertensive state is maintained by an elevation in blood 
volume, which in turn increases cardiac output by the Frank-Starling relationship.  
Diuretic drugs, which enhance the removal of sodium and water by the kidneys and 
thereby decrease blood volume, are very effective in the treatment of hypertension. 
Hypertension is also commonly treated with drugs that decrease cardiac output. These 
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cardioinhibitory drugs either block beta-adrenoceptors on the heart (i.e., beta-
blockers) or L-type calcium channels (i.e., calcium-channel blockers), which 
decreases cardiac output by decreasing heart rate and contractility (inotropy). 
Vasodilator drugs, which decrease systemic vascular resistance, are also used to treat 
hypertension. Included in these drugs are alpha-adeno receptor antagonists (alpha-
blockers), direct-acting vasodilators, angiotensin -converting enzyme inhibitors and 
angiotensin  receptor blockers 
Prevention of Hypertension: 
          Much of the disease burden of high blood pressure is experienced by people 
who are not labelled as hypertensive. Consequently, population strategies are required 
to reduce the consequences of high blood pressure and reduce the need for 
antihypertensive drug therapy. Lifestyle changes are recommended to lower blood 
pressure, before starting drug therapy. The  following are the primary preventive 
measures of  hypertension: 
 maintaining normal body weight for adults (e.g. body mass index 20–
25 kg/m
2
) 
 reducing dietary sodium intake to <100 mmol/ day (<6 g of sodium chloride or 
<2.4 g of sodium per day) 
 engage in regular aerobic physical activity such as brisk walking (≥30 min per 
day, most days of the week) 
 limit alcohol consumption to no more than 3 units/day in men and no more 
than 2 units/day in women 
 consume a diet rich in fruit and vegetables (e.g. at least five portions per day)
   
 
 
 
 
 
 
 
LITERATURE 
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2. LITERATURE SURVEY 
 
2.1. Literature Review: 
 
Recent advancement in Microsphere drug delivery systems: 
 
1) Anuj chawala., et al. (2012) was to prepare site specific drug delivery of 
naproxe sodium using sodium alginate and Eudragit S-100 as a mucoadhesive 
and pH-sensitive polymer, respectively Core microspheres of alginate were 
prepared by a modified emulsification method followed by cross-linking with 
CaCl2, which was further coated with the pH dependent polymer Eudragit S-100 
(2.5 or 5 %) to prevent drug release in the upper gastro intestinal environment. 
Drug release from all sodium alginate microsphere formulations followed 
Higuchi kinetics. Moreover, drug release from Eudragit S-100 coated 
microspheres followed the Korsmeyer-Peppas equation with a Fickian kinetics 
mechanism. 
2) Bipul nath. , et al. (2012) objective of present investigation was to evaluate the 
entrapment efficiency of the anti-HIV drug, zidovudine, using two Eudragit 
polymers of different permeability characteristics and to study the effect of this 
entrapment on the drug release properties. The release rate of zidovudine from 
Eudragit RS 100 microspheres was much lower than that from Eudragit RL 100 
microspheres. Evaluation of release data reveals that release of zidovudine from 
Eudragit RL 100 microspheres followed the Higuchi rule, whereas Eudragit RS 
100 microspheres exhibited an initial burst release, a lag period for entry of 
surrounding dissolution medium into polymer matrix and finally, diffusion of drug 
through the wall material. 
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3) Bhaskar mazumder., et al. (2012) aim of this study is to prepare and 
characterize the microspheres of chlorpheniramine maleate (CPM) with the 
combination of cellulose derivatives: ethyl cellulose and cellulose acetate. 
Microspheres were prepared with the combination of ethyl cellulose and cellulose 
acetate using oil-in-oil emulsion solvent evaporation method. Microspheres were 
characterized by particle size analysis, percentage yield, and entrapment 
efficiency, scanning electron microscopy (SEM), Fourier transform infrared (FT-
IR) spectroscopy, In-vitro release studies and release kinetics. The analysis of 
dissolution kinetic data shows that it follows Higuchi model then zero order 
followed by first order. 
4) Khaled M., et al. (2012) aim of this work was to formulate and evaluate 
controlled-release oxypentifylline (OXP) microspheres that fulfill the 
requirements for extended release medications using Ammonio Methacrylate 
Copolymer RS100 as polymeric material. The microspheres were prepared by 
quasi-emulsion solvent diffusion technique. The effect of process variables such 
as a drug to polymer ratio, stirring rate, and concentration of emulsifier on mean 
particle size, yield, entrapment efficiency and in-vitro release characteristics of 
microspheres were studied. This study showed that Ammonio Methacrylate 
Copolymer RS100 can be used successfully to sustain the release of OXP. 
5) Prasanth Singh.,  et al. (2012) the present work is to formulate and evaluate 
Ivabradine HCl (IBH) microspheres using egg albumin with the aim to get the 
best possible drug- polymer ratio giving the sustained drug release. IBH loaded 
egg albumin microspheres were prepared by heat denaturation technique. 
Various evaluation parameters were assessed, with a view to obtain sustained 
release of drug. The prepared IBH microspheres were then subjected to FTIR, 
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SEM, particle size and size distribution, % yield, % drug loading, entrapment 
efficiency, In-vitro dissolution studies, release kinetics and DSC. The in-vitro 
dissolution data maximum of 73.26% cum. drug release was obtained in the IBH 
loaded microspheres. The in-vitro performance of IBH microspheres showed that 
sustained release was dependent upon the polymer concentration. 
6) T.S Keerthi., et al. (2012) studied about design and characterization of 
microspheres of anti-hypertensive drug (losartan) using biodegradable natural 
polymer. The particle size distribution, entrapment efficiency and their release 
profile were investigated. Hence the drug release from the microspheres in a 
controlled manner in a regular fashion over extended period of time in 
comparision to all formulations. The microspheres found to be sustained for 12 
hours and successful for oral drug delivery. 
7) T.  Sudhamani.,  et al. (2012) was formulated Ibuprofen microspheres 
by using Ethyl cellulose as carrier. These ethyl cellulose microspheres were 
prepared by the solvent evaporation method. The prepared microspheres were 
subjected to various evaluations and in- vitro release studies. Highest percentage 
of loading was obtained by increasing the amount of ibuprofen with respect to 
polymer. The particle sizes of the prepared microspheres were determined by 
optical microscopy and SEM analysis. The prepared microspheres had good 
spherical geometry with smooth surface as evidence by SEM. 
8) Vidhya Kumari., et al. (2012) The main objective of this study was to 
formulate, develop and characterize Ofloxacin microspheres to prolong the release 
rate so as to decrease the necessity of multiple dosings especially in patients with 
renal impairment. The Ofloxacin microspheres were prepared using natural 
polymers by non-ionic cross linking technique. The prepared microspheres were 
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evaluated for percentage drug loading, entrapment efficiency, surface 
morphology, and in-vitro release characteristics to identify the effect of addition 
of these polymers .Cumulative release data were fitted into kinetic models Drug 
loading was found to increase with the increase in the concentration of 
encapsulating polymer, chitosan, sodium alginate and gelatin concentration. Drug 
release obeyed the first order kinetics. 
9) G. Dinesh babu., et al. (2011) was prepared and evaluated the Diclofenac 
potassium (DP) microspheres were prepared by using Double Emulsion-solvent 
evaporation method with ethyl cellulose (EC) and Eudragit polymers. By using 
different formulation variables, eight different formulations were prepared. The 
resulting microspheres obtained, were more spherical in shape and showed more 
entrapment efficiency. The size of the microspheres varied between 346-695 μm 
and as high as 96.48% loading efficiency for Eudragit and 77.36% for EC was 
obtained. In-vitro release study was carried out  EC microspheres released 23% of 
drug and Eudragit released 7% of drug. After 4 hours of dissolution 78% 
diclofenac potassium was released from EC microspheres and 92.35% of drug was 
released from Eudragit microspheres. 
10) Hongfei Liu.,  et al. (2011) was to fabricate novel ambroxol hydrochloride 
carboxy methyl chitosan microspheres were investigated by X-ray diffraction; 
the results showed that the drug chemically bonds to the ion exchangeable 
structure of the microspheres. The evaluation of the microspheres was 
investigated by dynamic light scattering, scanning electron microscopy (SEM) 
and UV spectrophotometer. Finally the In-vitro drug release was tested in 
different ionic concentration dissolution medium the results showed that the 
microspheres had a controlled release profile for 8 h In-vitro without obvious 
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burst release. 
11) Mohan raj palanisamy.,  et al. (2011) was developed to optimize the drug 
release pattern of a sustained release dosage form of metoprolol succinate. The 
preparation of MS (metoprolol succinate) microspheres was carried out using 
poly (ε-caprolactone) at different polymer: drug ratios from 1: 1 to 7: 1 and 10: 1 
(F1 to F7 and F8) by the emulsion-solvent evaporation method. Physico 
chemical characterization of different ratios of formulations (F1 to F8) of 
microspheres was carried out such as the drug content, drug entrapped, particle 
size, bulk density and angle of repose. The In-vitro drug release over 24 h was 
performed by the method specified in USP XXIV. It was found that the drug 
release kinetics followed the Korsmeyer–Peppas equation. This approach 
optimizes the properties of the sustained release microspheres of metoprolol 
succinate, which can minimize both drugdose, and frequency of dosing. 
12) Rahul nair.,  et al. (2011) aimed to prepare and characterize mefenemic acid 
microspheres using chitosan prepared by emulsion cross linking method to 
improve the oral bioavailability by reducing the gastrointestinal and renal 
effects. The in vivo studies of microspheres in albino rats demonstrated 
significant analgesic and anti-inflammatory activities of microspheres for longer 
period of time successfully. 
13) Chinna Gangadhar B., et al. (2010) The aim of this study was to formulate 
and evaluate microspheres as controlled release preparations of a highly water-
insoluble drug, Indomethacin, using natural polymer, Egg albumin; semi 
synthetic polymer, Ethyl cellulose and Synthetic polymer, Meth acrylic acid 
esters (Eudragit L 100) as the retardant materials. Microspheres were prepared 
by solvent evaporation method and Phase separation co-acervation method. The 
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prepared microspheres were evaluated for their micromeritic properties, drug 
content and encapsulation efficiency and characterized by Fourier transform 
infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM). The 
In-vitro release studies was performed by buffer change method pH 1.2, 
carbonate buffer (acidic) and pH 7.4, phosphate buffer (Alkaline). The best-fit 
release kinetics was achieved with Koresmeyer-Peppas plot followed by zero 
order and First order. The release of Indomethacin was influenced by the drug to 
polymer ratio and particle size &was found to be both diffusion and dissolution 
controlled. 
14) Gambhire Makarand., et al. (2010)  was  studied  the  preparation  and  
physico- chemical evaluation of Rifampicin microspheres . Rifampicin has poor 
and variable bioavailability. The present investigation was aimed to develop RIF 
loaded porous microspheres as a controlled release dosage form. Eudragit based 
porous microspheres of RIF were prepared by emulsion solvent diffusion 
method. Prepared porous microspheres were evaluated for its entrapment 
efficacy, morphology, thermal behavior, crystalline nature, in-vitro drug release 
and stability in simulated gastric fluid. The results obtained from the present 
investigation concluded that Rifampicin loaded porous microspheres are suitable 
for developing oral controlled release dosage form. 
15)  Karthikeyan.,  et al. (2010) was formulated microspheres with Metoprolol                
tartrate was to micro encapsulate the Anti-Hypertensive drug was to provide 
sustained release and maintain constant the plasma drug concentration 
.Metoprolol was microencapsulated with Eudragit-RS100 using solvent 
evaporation techniques. The effect of different formulation variables 
including the drug polymer ratio. Metoprolol microspheres was subjected to 
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micromeritic properties including the Angle of Repose, Bulk density, Carr’s 
index, Haugner’s ratio and Particle size determination. Metoprolol 
microspheres were subjected to Drug Loading, invitro drug release as well as 
for SEM and kinetic drug release. 
16) A.R. Shabaraya.,  et al.  (2009)   was aimed to prepare Metoprolol 
tartrate was formulated as biodegradable microspheres using chitosan  by 
the phase separation emulsification technique. Microspheres of drugs to 
carriers were prepared and thermally cross-linked. The size range of the 
microspheres varies from3.5 to 31.5µm. UV and DSC studies were 
carried out to confirm the presence and stability of the drug in the 
microspheres. Short-term stability studies were carried out at different 
temperatures. In-vitro release studies were carried out at different pH for 
a period of 10 h and compared with pure drug. The release of metoprolol 
tartrate from the chitosan microspheres was found to be sustained. 
17)  A.Balaiah.,  et al. (2008) was to prepare oral microspheres of levetiracetam 
with a view to reduce the frequency of dosing and to attain steady state drug 
levels. Levetiracetam is a second-generation antiepileptic agent useful in the 
treatment of partial onset and myoclonic seizures. Microspheres are suitable drug 
delivery system for such drug candidate. Microspheres were prepared by various 
methods like w/o/o double emulsion solvent diffusion and w/o/w double 
emulsion solvent evaporation technique. Pre formulation studies were carried out 
to rule out any drug-polymer interactions by DSC technique. In the In-vitro 
release studies initial burst release was observed from all the formulations.  The 
data obtained from In-vitro release showed highest correlation with Higuchi 
model and the drug release was found to be diffusion controlled. 
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18)  S K Basu., et al. (2008) Nitrendipne-loaded Eudragit RL 100 microspheres 
were prepared by an emulsion-solvent evaporation method using ethanol/liquid 
paraffin system. The resultant microspheres were evaluated for average particle 
size, drug loading, In-vitro drug release and release kinetics. FTIR spectrometry, 
scanning electron microscopy, differential scanning calorimetry and x-ray powder 
diffractometry were used to investigate the physical state of the drug in the 
microspheres. 
19) Meral YUCE., et al. (2008) aim of this work was to investigate the 
influence of process variation in polymer type via viscosity grades of 
ethylcellulose N10 and N100, drug to polymer ratio, stirring rate of the propeller 
and surfactant type on the micromeritic properties of microspheres such as 
particle size distribution, bulk and tapped density, surface topography, tangent of 
angle of repose, compressibility index, Hausner ratio and flow rates. Ethyl 
cellulose N10 and N100 membrane materials indicated difference in release 
patterns of microspheres. Microspheres exhibited lower burst effect with 
decreased drug release rate, when the drug was incorporated with ethyl cellulose 
N100 and higher ratio of each polymer. Therefore, indomethacin release from 
ethyl cellulose microspheres could not be evaluated by any of the kinetic models. 
20)  V.V Prasanth., et al. (2008) were aimed to prepare Salbutamol sulphate 
(SS) loaded microspheres were prepared by solvent evaporation method with 
combination of hydroxy propyl methyl cellulose and Carbopol polymers in 
various proportions. A total of eleven formulations were prepared. It was 
confirmed with the results of micromeretic properties like swelling index particle 
size, entrapment efficiency property that all the selected formulations showed 
good flow property. Release data were analyzed based on Highuchi kinetics and 
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Korsmeyer-Peppas equation and all the selected formulations showed good fit to 
Highuchi  model. Stability studies showed almost negligible changes in particle 
size, entrapment efficiency and drug release throughout the study period. 
21) Sunit kumar sahoo., et al. (2005) Microspheres were prepared by solvent 
evaporation method using an acetone / liquid paraffin system. Magnesium 
stearate . The prepared microspheres were characterized for their micromeritic 
properties and drug loading, as well by fourier transform infrared spectroscopy 
(FTIR), differential scanning calorimetry, x-ray powder diffractometry and 
scanning electron microscopy. The In-vitro release studies were performed in pH 
6.8, phosphate buffer. The best-fit release kinetics was achieved with Higuchi 
plot followed by zero order and First order. The release of stavudine was 
influenced by the drug to polymer ratio and particle size & was found to be 
diffusion controlled. 
22)  Navneet Garud., et al. (2003)  were prepared Metformin microspheres for 
prolonged release by non-aqueous solvent evaporation method using various 
polymers, including ethyl cellulose(EC), hydroxypropyl methyl cellulose 
(HPMC), carbopol 934P (CA) and chitosan (CH) .The effect of process 
variables ,viz, drug/polymer ratio, stirring rate and type of polymer on the 
mean particle size, drug entrapment efficiency, percentage yield, drug content, 
micromeritic properties and drug release of the microspheres were studied. 
 
. 
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2.2  DRUG PROFILE 
 
METOPROLOL TARTRATE: 
 (IP., 2007; Merck Index., 1997; USP., 2009; Tripathi K.D., 2004) 
Metoprolol is the prototype of cardio selective (β1) blocker used in the 
treatment of several diseases cardiovascular system especially 
hypertension. It has the potency to block cardiac stimulation and it also 
induce vasodilatation. The active substance metoprolol is employed 
either as metoprolol succinate or metoprolol tartrate i.e 100 mg of 
metoprolol tartrate corresponds to 95 mg of metoprolol succinate. The 
tartrate is immediate release and the succinate is an extended release . 
Chemical name: 
(RS)-1-isopropylamino-3-p- (2-methoxyethyl) phenoxypropan-2-ol (2R,3R)-tartrate 
  
Structural formula: 
 
    
      
 
 
Category: 
             Adrenergic Agents, Adrenergic beta-Antagonists, Anti-Arrhythmia 
Agents Antihypertensive Agents, Sympatholytics  
Dose: 
 Conventional dose: - Initially 50 to 100 mg daily in single or divided doses may 
increases weekly to 400 mg daily. 
Maintenance dose: - 100 to 200 mg daily 
 Extended release preparation: - 25 to 100 mg once daily. 
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 C. Physical properties: 
 
 Molecular formula     : C15H25NO3)2, C4H6O6 
 
 Molecular weight       : 684.8 g/mol 
 
 Description                   : White powder or colorless crystals 
 
 Odour                          : Odour less 
 
Taste                             : Metallic 
 
Melting point               : Melt at about 121 º to 124 ºC (BP) 
 
Dissociation constant (pKa):  9.7 
 
Solubility                      : Very soluble in water; freely soluble in ethanol;        
slightly soluble in acetone 
Storage                       : Store in well closed container 
D. Mechanism of action: 
Metoprolol competes with adrenergic neurotransmitters such as 
catecholamines for binding at beta (1)-adrenergic receptors in the heart and vascular 
smooth muscle.  Beta (1)-receptor blockade results in a decrease in heart rate, cardiac 
output, blood pressure. 
 E.  Pharmacokinetics: 
 Oral bioavailability                           : 40 to 50% 
 
 Protein binding                                  : 12 % 
 
 Volume of distribution                      : 4 L/kg. 
 
 Half life                                               : 3-7 hour 
 
F.  Absorption: 
Metoprolol is readily and completely absorbed from the gastrointestinal tract, 
but is subjected to very considerable first pass metabolism in the liver and the 
bioavailability is only about 38%. Peak plasma concentrations vary widely and occur 
about 1.5 to 2 hrs after a single oral dose.  
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G.  Distribution: 
 
Metoprolol is widely distributed. It crosses the blood brain barrier the 
placenta and is distributed into breast milk. The apparent volume of distribution 
range from about 2.5 liters/kg to 5.0 liters/kg and approximately 90% bound to 
plasma protein. 
H.  Metabolism:  
 
  It is extensively metabolized in the liver by oxidative deamination, O-
dealkylation followed by oxidation and aliphatic hydroxylation. Minimal hepatic 
m e t a b o l i s m  by aldehyde oxidase, alcohol dehydrogenase, and aldehyde 
dehydrogenase to form inactive metabolites. 
 I.  Excretion: 
The metabolites are excreted in the urine together with only small amounts of 
unchanged metoprolol.  
Therapeutic uses: 
 Hypertension,  
Angina pectoris 
 Cardiac arrhythmias, 
 Myocardial infraction, 
 Migraine prophylaxis and Hyperthyroidism. 
Drug interactions: 
 Beta-blocker and Calcium channel blocker have additive effect on the cardiac 
conducting system. 
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Toxicity: 
LD50=5500 mg/kg (orally in rats), toxic effects include bradycardia, hypotension, 
bronchospasm, and cardiac failure. LD50=2090 mg/kg (orally in mice). 
Dosage forms: 
Table 2.1. Dosage forms and routes of administration of Metoprolol 
Form Route 
Liquid Intravenous 
Solution Intravenous 
Film Oral 
Film extended release Oral 
 
Marketed preparations: 
Beloc, Betaloc, Lopresor, Lopresoretic, Lopressor, Lopressor, HCT,Metroprolol, 
Prelis, Selo-Zok, Seloken, Selopral, Toprol, Toprol- XL
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2.3. POLYMERS PROFILE:   
 2.3.1. EGG ALBUMIN 
Synonyms : Ovalbumin, Egg white, Dried egg white 
CAS registry number :  9006-50-2 
Empirical formula         :   C6H8N2O4 
 
Molecular weight              :   44.3 Kda
 
 
Extinction Coefficient     : E1%= 6.9-7.6(280nm) 1   
 
Structural formula            : 
 
 
Denaturation Point           :  Egg albumin denatures at 840
0
C      
 
 Descriptions:  
             It is a phosphorylated- glycoprotein. The peptide portion of the molecule 
consists of 385 residues & has a molecular weight of 42.7 Kda.This sequence 
completely agrees with the reported mRNA sequence.
 
 
The carbohydrate & Phosphate portions account for an additional 1428 & 160 
gm per mole respectively, giving a total molecular weight of 44.3 Kda. 
Egg albumin in its structure has the following Amino acids.
 
 
                              20Lys, 10Tyr, 6Cys, 14 Asp & 33 Glu. 
 
The above amino acids make egg albumin suitable for conjugation. 
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Typical properties: 
       Density                     : 430 kg/cm
3
                
                   Boiling point           :  251.7 °C at 760 mm 
                 Moisture content    : contains 5 % to 8 % and not  
 Solubility                : soluble in ethanol, soluble in water. 
 
 Surface tension    :  12.5 % solution , pH 7.8, 24ºC at 49.9 dynes cm-1 
 
    
 Stability and storage: 
 
Egg albumin powder stable at room temperature . It should be stored in dry 
and clean, free from foreign smell, recommended storage temperature 8-26
o
C;day 
fluctuations of temperature not more than4
o
C.  
Incompatibilities:  
It is incompatible with other materials and strong oxidizing agent. 
Handling precautions: 
 
Observe normal precautions appropriate to the circumstances and quantity 
of material handled.  
Regulatory statuses: 
 
Included in the FDA Inactive Ingredients data base (oral tablets microspheres, film 
coating, and IV injections). Included in non parenteral medicines licensed in the UK. 
Included in the Canadian List of Acceptable Non-medicinal Ingredients.
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    2.3.2 ETHYL CELLULOSE 
Nonproprietary Names: 
BP  : Ethyl cellulose 
PhEur  : Ethyl cellulose 
USP-NF : Ethyl cellulose 
Synonyms: 
Aquacoat ECD, Aqualon, Ashacel, E462,Ethocel, ethylcellulosum 
Sure lease. 
Chemical Name            : Cellulose ethyl ether  
CAS Registry Number: [9004-57-3] 
Empirical Formula and Molecular Weight: Ethyl cellulose is partially ethoxylated. 
Ethyl cellulose with complete ethoxyl substitution (DS = 3) is C12H23O6 (C12H22O5) 
nC12H23O5 where n can vary to provide a Wide variety of molecular weights. Ethyl 
cellulose, an ethyl ether of cellulose, is a long-chain polymer of b- anhydroglucose 
units joined together by acetal linkages. 
Structural Formula: 
 
Functional Category: 
Coating agent, flavoring agent, tablet binder, tablet filler, viscosity increasing agent. 
Description: 
Ethyl cellulose is a tasteless, free-flowing, and white to light tan-colored powder. 
Color: white to light tan-colored powder 
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Odor      : odorless. 
Taste      : tasteless 
Texture  : powder  
Solubility: 
Ethyl cellulose is practically insoluble in glycerin, propylene glycol, and water. Ethyl 
cellulose that contains less than 46.5% of ethoxyl groups is freely soluble in 
chloroform, methyl acetate, and tetrahydrofuran, and in mixtures of aromatic 
hydrocarbons with ethanol (95%). Ethyl cellulose that contains not less than 46.5% of 
ethoxyl groups is freely soluble in chloroform, ethanol (95%), ethyl acetate, methanol, 
and toluene. 
Stability and Storage Conditions: 
Ethyl cellulose is a stable, slightly hygroscopic material. It is chemically resistant to 
alkalis, both dilute and concentrated, and to salt solutions, although it is more 
sensitive to acidic materials than are cellulose esters. Ethyl cellulose is subject to 
oxidative degradation in the presence of sunlight or UV light at elevated temperatures. 
This may be prevented by the use of antioxidant and chemical additives that absorb 
light in the 230–340nm range. Ethyl cellulose should be stored at a temperature not 
exceeding328
◦
C (908F) in a dry area away from all sources of heat. It should not be 
stored next to peroxides or other oxidizing agents. 
Incompatibilities: 
   Incompatible with paraffin wax and microcrystalline wax. 
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Applications in Pharmaceutical Formulation or Technology 
 Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. 
 The main use of ethyl cellulose in oral formulations is as a hydrophobic 
coating agent for tablets and granules. Ethyl cellulose coatings are used to 
modify the release of a drug, to mask an unpleasant taste, or to improve the 
stability of a formulation. For example where granules are coated with ethyl 
cellulose to inhibit oxidation. 
  Modified-release tablet formulations may also beProduced using ethyl 
cellulose as a matrix former. Ethyl cellulose, dissolved in an organic solvent or 
solvent mixture, can be used on its own to produce water-insoluble films. 
 Drug release through ethyl cellulose-coated dosage forms can be controlled by 
diffusion through the film coating. This can be a slow process unless a large 
surface area (e.g. capsules or granules compared with tablets) is utilized. In 
those instances, aqueous ethyl cellulose dispersions are generally used to coat 
granules or capsules. 
 Ethyl cellulose-coated beads and granules have also demonstrated the ability 
to absorb pressure and hence protect the coating from Fracture during 
compression.  
 High-viscosity grades of ethyl cellulose are used in drug microencapsulation.  
 Release of a drug from an ethyl cellulose microcapsule is a function of the 
microcapsule wall thickness and surface area. 
  In tablet formulations, ethyl cellulose may additionally be employed as a 
binder, the ethyl cellulose being blended dry or wet granulated with a solvent 
such as ethanol (95%). 
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 Ethyl cellulose produces hard tablets with low friability, although they may 
demonstrate poor dissolution. Ethyl cellulose has also been used as an agent 
for delivering therapeutic agents from oral (e.g. dental) appliances. 
 In topical formulations, ethyl cellulose is used as a thickening agent in creams, 
lotions, or gels, provided an appropriate solvent is used. Ethyl cellulose has 
been studied as a stabilizer for emulsions. Ethyl cellulose is additionally used 
in cosmetics and food products. 
Table I: Uses of ethyl cellulose. 
Use Concentration (%) 
Microencapsulation 10.0–20.0 
Sustained-release tablet coating 3.0–20.0 
Tablet coating 1.0–3.0 
Tablet granulation 1.0–3.0 
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2.3.3. EUDRAGIT RL 100 
 Non-proprietary names: 
 
 Ph. Eur: Ammonio Methacrylate Copolymer, Type  
 
 USP/NF: Ammonio Methacrylate Copolymer, Type A - NF 
 
JPE: Aminoalkyl Methacrylate Copolymer RS 
 
Synonyms   :  amino methacrylate copolymer  
C.A.S. No.   : 25086 – 15 – 1  
Structure   :           
       
Chemical/IUPAC name : Poly (methacylic acid-co-methyl methacrylate) 
1:2 
 INCI name   :  Acrylates Copolymer 
Description   : White powders with a faint characteristic odour. 
 Functional category:  
  Film former; tablet binder; tablet 
diluents. 
Application in pharmaceutical formulation or technology: 
EuagitR100 are used to form water insoluble film coating agent for 
sustained release products. Eudragit RL 100 films are more permeable than those 
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of eudragit RS, and films of varying permeability can be obtained by mixing the 
two types together. 
Solubility:            
1gm of Eudragit RL 100 dissolves in 7 g methanol, ethanol, in aqueous 
isopropyl alcohol ethanol, and acetone (containing approx.3% water),. 
Film formation:  
When the test solution is poured onto a glass plate, a clear film forms upon 
evaporation of the solvent. 
Characteristics: 
 Granulation of drug substances in powder form for controlled release 
 Effective and stable enteric coatings with a fast dissolution in the upper Bowel 
 Site specific drug delivery in intestine by combination with Eudragit S grades 
 Variable release profiles 
Applications:  
 Eudragit is widely used in oral pharmaceutical formulations, especially in 
targeting drug delivery system in GIT. Eudragit is used to prepare sustained-release 
preparations. 
Loss on Drying:  Max. 5.0 % according to "Dry substance / Residue on evaporation." 
Viscosity (dynamic): 50 - 200 mPas.                                                          
Stability and Storage:  
Minimum stability dates are given on the product labels and batch-related 
Certificates of Analysis. Protect from warm temperatures (USP, General Notices). 
Protect against moisture.                     
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3. AIM AND OBJECTIVES 
 Metoprolol tartrate is a competitive β1- selective adrenergic antagonist. It is 
widely used for the treatment of hyper tension, angina pectoris and prophylaxis of 
migraine receptors. This drug is water soluble although it is well absorbed in the 
gastro intestinal tract and its bio availability is low (40 to 50%). It has a short 
biological half life (3 to 4 hours) and is usually administered in a dose of 25 to100 mg 
two times daily in order to maintain effective concentrations throughout the day. In 
long -term therapy, fluctuation in the plasma concentration, with high concentration 
peaks are common for drugs with rapid absorption and elimination if plasma levels 
markedly exceed therapeutic levels. Such characteristics make Metoprolol tartrate as 
best suitable drug candidates for controlled drug delivery. 
Microsphere formulation offers a number of advantages in therapeutics where 
the controlled release of drugs as well as predictable and reproducible drug release 
kinetics is important factors among them. Metoprolol tartrate is the most widely used 
anti- hypertensive agent. 
      The aim of the present work was to formulate Metoprolol Tartrate 
microspheres using natural, semi synthetic and synthetic polymers containing in order 
to provide a controlled release effect and relatively constant effective level of these 
drugs in the treatment of major Hypertension disease.  
 The main objective of the present investigation was to develop and to 
evaluate the Metoprolol tartrate microspheres by using natural polymer-Egg albumin; 
semi synthetic polymer-Ethyl cellulose and synthetic polymers-Eudragit RL 100.The 
effect of variable concentration of polymers on the characteristics of the microspheres 
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will be studied. Since these polymers are biocompatible it has been reported in 
reputed journals. 
 Since nine formulations were prepared with varying drug and polymer ratio. 
These formulations were subjected to evaluate the various parameters like 
percentage yield, drug content, entrapment efficiency, particle size, FTIR, DSC, 
SEM,    In-vitro drug release, Kinetic drug release and stability studies. 
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5. MATERIALS AND EQUIPMENTS 
 
5.1. List of Materials used with Sources 
  Table 5.1: List of Polymers and Excipients with source 
 
S.No. Ingredients Supplier 
 
1 
 
Metoprolol Tartrate 
Madras pharmaceuticals pvt  
Ltd, Chennai. 
 
 
 
2 
 
Egg albumin 
Dr. Reddys pharmaceuticals 
limited, Mumbai. 
3 Ethyl cellulose S d fine-chem limited, Mumbai. 
4 Eudragit RL 100 Hi-media laboratories, Mumbai. 
5 Coconut oil marico. limited, Mumbai. 
6   Light liquid paraffin Qualigens fine chemicals, Mumbai. 
7 Sodium lauryl sulphate S d fine-chem limited, Mumbai. 
8 Tween 80 Fischer scientific chemicals, Mumbai. 
9 Acetone Fischer scientific chemicals, Mumbai. 
10 Ethanol Fischer scientific chemicals, Mumbai. 
11 n-Hexane Loba Chemicals Pvt.Ltd. Mumbai. 
12 Hydrochloric acid S d fine-chem limited, Mumbai. 
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  5.2. List of Equipments used with model: 
                            Table 5.2:  List of Equipments with model/make 
 
S.No Equipments Model/ Make 
1 Electronic balance Shimadzu BL-220H. 
2 Mechanical stirrer 2200MH, Soltech srl,  Soluzioni 
 
Tecnologirhe, Milano, Italy. 
3 Magnetic stirrer Labtech, Ambala. 
4 Digital pH meter Elico scientifics-L1610, Mumbai. 
5 UV spectrophotometer Shimadzu-1700 Pharmaspec 
UV- VISIBLE 
spectrophotometer. 6 FTIR spectrophotometer Shimadzu S4008. 
7 Differential scanning calorimeter Shimadzu DSC 60 with DTA, 
Japan. 
8 Scanning electron microscope SEM, JSM-6360LV Tokyo, 
Japan.  
9 Humidity chamber Lab tech. 
10 USP Tablet Dissolution 
Apparatus Type II 
 
USP XXIV (Electro Lab, Mumbai). 
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6. PRE-FORMULATION STUDIES 
 
Preformulation Study:                                                                            (Jens T., 2000) 
 
Before the formulation of a product should be investigation of physical and 
chemical properties of a drug substance alone to effective, stable and safe dosage 
form. It is the first step in rational development of dosage form. 
6.1. Identification of Drug: 
 
The preliminary studies were carried out by testing of different physical and 
chemical properties of drug as follows. 
6.1.1. Organoleptic Properties of Drug:                                (Lachman L., 1991) 
 
The Organoleptic properties like physical state, color, taste, odor etc., of the 
drug was reported with help of the descriptive terminology. It helps to identify the 
drug. 
6.1.2. Melting Point:                                                                               
 
It is the easy way to identify the drug. The melting point of Metoprolol 
tartrate was tested by use of a laboratory melting point apparatus with capillary tube 
method a procedure given in official monographs. 
6.1.3. Solubility Profile:                                                                          (IP., 2007) 
 
It is important to know about solubility characteristic of a drug in aqueous 
system, since they must possess some limited aqueous solubility to elicit a therapeutic 
response.   The   solubility   of   drug   was   recorded   by   using   various   descriptive 
terminology specified in Indian pharmacopoeia, 2007. 
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Table 6.1: Description of solubility 
 
Descriptive term Parts of solvent required for 1 part of 
solute 
Very soluble Less than1 
 
 
1 
Freely soluble From 1 to10 
Soluble From 10 to30 
Sparingly soluble From 30 to100 
Slightly soluble From 100 to 1,000 
Very slightly soluble From 1,000 to 10,000 
Practically insoluble Greater than or equal to 10,000 
 
 
6.1.4. UV Spectroscopy (λ max):           (Venkatalakshmi Ranganathan., 2011) 
 
       The absorption m a x i m u m  o f  the standard s o l u t i o n  was  scanned 
b e tw een 200- 400 nm regions on Shimadzu-1700 Pharmaspec UV-visible 
spectrophotometer. The absorption maximum obtained with the substance being 
examined corresponds in position and relative intensity to those in the reference 
spectrum. 
6.1.4.1. Development of Standard Curve of Metoprolol tartrate in Distilled 
Water:       
Preparation of Stock Solution of Metoprolol tartrate in Distilled 
Water: 
 
Weighed accurately about 100 mg of Metoprolol tartrate was dissolved in little 
quantity of  distilled  water  and  volume  was  adjusted  to  100  ml  with  the  same  to  
prepare standard solution having concentration of 1000 µg/ml. From this solution, 
pipette out 10 ml and made up to 100 ml with distilled water to produce 100 µg/ml. 
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Procedure: 
 
From  the  stock  solution,  aliquots  of  1, 2, 3, 4 and 5 ml  were transferred  to 
10 ml volumetric  flasks  and final volume  was made to 10 ml with distilled  water  
to  get  10  to  50  µg/ml.  Absorbance  values  of  these  solutions  were measured  
against  blank  (Distilled  water)  at  274.5  nm  using  UV-visible spectrophotometer. 
6.1.4.2. Development of Standard Curve of Metoprolol tartrate in 
0.1N HCl: 
Preparation of 0.1N HCl: 
    0.1N HCl was prepared according to I.P. 1996. Accurately 8.5 ml of HCl was 
taken and diluted with freshly prepared distilled water to produce 1000 ml. 
  Preparation of Stock Solution of Metoprolol tartrate in 0.1 N HCl: 
Weighed accurately about 100 mg of Metoprolol tartrate was dissolved in little 
quantity of 0.1N HCl and volume was adjusted to 100 ml with the same to prepare 
standard solution having concentration  of 1000 µg/ml. From this solution, pipette out 
10 ml and made up to 100 ml with 0.1N HCl to produce 100µg/ml. 
 Procedure: 
From the stock solution, aliquots of 1, 2, 3, 4 and 5 ml were transferred to 10 ml 
volumetric flasks and final volume was made to 10 ml with 0.1N HCl to get 10 to 50 
µg/ml. Absorbance values of these solutions were measured against blank 0.1 N HCl 
at 274.5 nm using UV-visible spectrophotometer. 
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6.1.4.3. Development of Standard Curve of Metoprolol  tartrate  in pH 7.4 
Phosphate Buffer: 
Preparation of 0.2M Potassium Dihydrogen phosphate: 
 
Dissolved 27.218 gm of potassium dihydrogen phosphate in water and made 
up to 1000 ml. 
 Preparation of 0.2M Sodium hydroxide: 
Dissolved 8 gm of sodium hydroxide pellets in distilled water and made up to 
1000 ml. 
Preparation of Phosphate Buffer pH 7.4: 
 
Phosphate buffer pH 7.4 was prepared according to I.P. 2007. A quantity of 50 
ml of 0.2M potassium dihydrogen phosphate and 39.1 ml of 0.2M sodium hydroxide 
was diluted with freshly prepared distilled water to produce 200 ml. 
Preparation of Stock Solution of Metoprolol tartrate in pH 7.4 Phosphate 
Buffer: 
 
Weighed accurately about 100 mg of Metoprolol tartrate was dissolved in little 
quantity of pH 7.4 phosphate buffer and volume was adjusted to 100 ml with the 
same to prepare standard solution having concentration of 1000 µg/ml. From this 
solution, pipette out 10 ml and made up to 100 ml with pH 7.4 phosphate buffer to 
produce 100 µg/ml. 
Procedure: 
From the stock  solution,  aliquots  of  1, 2, 3, 4  and 5  ml  were transferred to 10 
ml volumetric flasks and final volume was made to 10 ml with pH 7.4 phosphate 
buffer to get10 to 50 µg/ml. Absorbance values of these solutions were measured against 
blank (Phosphate Buffer pH 7.4) at 274.5 nm using UV-visible spectrophotometer. 
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 6.1.5. Quantification of Drug: 
 
Accurately weighed 100 mg of Metoprolol tartrate was dissolved in little 
quantity of 0.1 N HCL and volume was adjusted to 100 ml with the same to prepare 
standard solution having concentration of 1000 µg/ml. From this solution, pipette 
out10 ml and made up to 100 ml with 0 . 1 N H C L  to produce 100µg/ml. From the 
above solution, aliquots of 2 ml were transferred to 10 ml volumetric flasks and final 
volume was made to 10 ml with 0.1 N HCL.  Absorbance values of these solutions 
were measured against blank 0 . 1 N  H C L  at 274.5 nm using Shimadzu-1700 
Pharmaspec UV-visible spectrophotometer. The percentage purity of drug was 
calculated by using calibration graph method (least square method). 
Fourier Transforms Infra-Red (FTIR) Spectroscopy: 
                             (Robert M. Silverstein, 2003; Becket A. H. and Stenlake J. B., 2005) 
FTIR study was carried out to check identity of drug. Infrared spectrum of 
Metoprolol tartrate was determined on Fourier transform Infrared Spectrophotometer using 
KBr dispersion method. The base line correction was done using dried potassium bromide. 
Then the spectrum of dried mixture of drug and potassium bromide was run followed by 
drug by using FTIR spectrophotometer. The absorption maximums in spectrum obtained 
with the substance being examined correspond in position and relative intensity to those in 
the reference spectrum. 
Loss on drying:                                             (Indian Pharmacopoeia, 2007) 
Loss on drying is the loss of weight expressed as percentage w/w resulting from 
volatile matter of any kind that can be driven off under specified condition. The test can be 
carried out on the well mixed sample of the substance. 
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      Initial weight of substance – Final weight of substance 
Loss on drying =     
                                           Initial weight of substance 
×100 
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7. FORMULATION OF MICROSPHERES 
 
Table.7.1: Formulation of Metoprolol Tartrate Microspheres  
 
S. 
NO 
FOMULATION 
CODE 
METOPROLOL 
TARTRATE(gm) 
EGG 
ALBUMIN(gm) 
ETHYL 
CELLULOSE(gm) 
EUDRAGIT 
RL 100 (gm) 
1 F1 1 1 - - 
2 F2 1 2 - - 
3 F3 1 3 - - 
4 F4 1 - 1 - 
5 F5 1 - 2 - 
6 F6 1 - 3 - 
7 F7 1 - - 1 
8 F8 1 - - 2 
9 F9 1 - - 3 
 
   Formulations F1, F2, and F3 – Metoprolol Tartrate + Egg albumin 
    Formulations F4, F5, and F6 – Metoprolol Tartrate + Ethyl cellulose 
    Formulations F7, F8, and F9 – Metoprolol Tartrate +Eudragit RL 100 
. 
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METHODS OF PREPARING MICROSPHERES: 
  The following are the methods used for the preparation of 
Microspheres. They are as follows 
   Emulsion polymerization method. 
   Solvent evaporation method      
 
PREPARATION OF EGG ALBUMIN MICROSPHERES BY PHASE 
SEPARATION AND EMULSION POLYMERIZATION METHOD: 
Phase separation emulsion polymerization method was employed for the preparation 
of microspheres. Polymeric drug solution was prepared by adding 1gm of drug 
(Metoprolol tartrate) to 10ml of 10% solution of Egg albumin and stirred continuously 
until uniform dispersion. In a separate beaker, to 86ml of coconut oil 1ml of 0.5% 
sodium lauryl sulphate was added drop-wise using 22 gauge needle into the organic 
phase and stirred continuously to form uniform dispersion. The temperature of the 
solution was gradually increased to 80
◦
C and stirred at this temperature for 2hours. 
The solution was cooled to room temperature was attained, 1ml of formaldehyde and 
20 ml of n-Hexane then followed by distilled water, dried and stored in air tight 
container until further analysis. 
 
 
Fig.7.1: Preparation of egg albumin microspheres 
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PREPARATION OF ETHYL CELLULOSE MICROSPHERES BY SOLVENT 
EVAPORATION METHOD: 
 Solvent evaporation method was employed for the preparation of 
microspheres, containing 1gm of ethyl cellulose was dissolved in 20ml of acetone and 
ethanol solution in the ratio (1:1).To the above polymeric solution, 1gm of metoprolol 
tartrate was added and dispersed. The resultant mixture was added drop-wise using 22 
gauge needle into 100ml oil phase containing 50 ml of coconut oil and 50 ml of light 
liquid paraffin containing 0.2ml of Tween 80. The resultant dispersion was stirred 
continuously using mechanical stirrer at 400 rpm for 3-4 hours. Then finally the 
microspheres were collected and washed with n-Hexane to remove the oil content 
followed by washing with distilled water thrice .The microspheres were then filtered, 
dried and stored in air tight container until further analysis. During the preparation 
procedure, emphasis is to be given on rpm and temperature for size and spherecity of 
the microspheres. 
 
PREPARATION OF EUDRAGIT RL 100 MICROSPHERES BY SOLVENT 
EVAPORATION METHOD: 
Solvent evaporation method was employed for the preparation of 
microspheres, containing 1gm of Eudragit RL 100 was dissolved in 20ml of acetone 
and ethanol solution in the ratio (1:1).To the above polymeric solution, 1gm of 
metoprolol tartrate was added and dispersed. The resultant mixture was added drop-
wise using 22 gauge needle into 100ml oil phase containing 50 ml of coconut oil and 
50 ml of light liquid paraffin containing 0.2ml of Tween 80. The resultant dispersion 
was stirred continuously using mechanical stirrer at 1500 rpm for 8 hours. Then 
finally the microspheres were collected and washed with n-Hexane to remove the oil 
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content followed by washing with distilled water thrice .The microspheres were then 
filtered, dried and stored in air tight container until further analysis. During the 
preparation procedure, emphasis is to be given on rpm and temperature for size and 
spherecity of the microspheres. 
 
 
 
 
Fig.7.2: Preparation of Eudragit RL 100 microspheres 
 
 
 
 
 
  
        
 
 
  
 
        EVALUATION       
OF MICROSPHERES.... 
Controlled Release Microspheres of Metoprolol tartrate                     Evaluation of Microspheres  
  
Adhiparasakthi College of Pharmacy, Melmaruvathur Page 80 
  
 
8. EVALUATION OF MICROSPHERES 
 
8. EVALUATION OF MICROSPHERES 
8.1. Percentage Yield:       (Venkatesan P et al., 2011; Bindhu Madhavi., et al., 2011) 
          The dried microspheres were weighed and percentage yield of the prepared 
microspheres was calculated by using the following formula. 
Percentage yield = (Weight of Microspheres/Weight of Polymer + drug) X 100 
8.2. Estimation of Drug content:     (Chinna gangadhar et al., 2010)   
         The prepared microspheres were powdered and passed through sieve no 
(85/120). The powder retained on the sieve 120 was taken for content uniformity 
studies. A weight of powder containing 100 mg of the drug was taken in a 100ml 
standard volumetric flask. To this of 0.1 N HCl solutions was added and made up to 
the mark with 0.1 N HCl solution and kept overnight. The final solution was filtered 
using what man filter paper. From this 10 ml was pipette out into a 100 ml standard 
volumetric flask and made up to the volume with 0.1 N HCl solution and estimated. 
                         Amount of drug found 
            Percentage drug content =                                                             × 100 
Label claim 
 
 8.3. Estimation of Entrapment efficiency:      (Chinna gangadhar et al., 2010) 
        To evaluate the amount of the drug inside the microspheres, an indirect method 
was used. Aliquots from the filtered solutions remaining after removal of the 
microspheres were assayed spectrophotometrically. The amount of drug entrapped 
was calculated from the difference between the total amount of drug added and the 
amount of drug found in the filtered solution. About 100 mg of microspheres were 
completely dissolved in 500 ml of phosphate buffer solutions (pH 7.4), and stirred for 
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1h. Then, 2 ml of solution was filtered and the concentration of drug was determined 
spectrophotometrically by UV. Efficiency of drug entrapment was calculated in terms 
of percentage drug entrapment (PDE) as per the following formula 
                                    W initial drug – W free drug 
Percentage drug entrapment efficiency =                                                       ×100  
                       W initial drug 
 
8.4. Particle size Analysis:                                     (A.R. Shabarya., et al.,2003) 
               Microspheres were dispersed in liquid paraffin and observed under 200 x 
magnification using an optical microscope. The size distribution was carried out by 
optical microscopy. An average of about 100 particles were counted and determined. 
8.5. Differential Scanning Calorimetry Study (DSC):                     (Jain N. K., 2008) 
Metoprolol tartrate powder was mixed with various polymers in the ratio of 
1:1. The mixture of drug with polymers to maximize the like hood of obscuring an 
interaction. Mixture should be examined under Nitrogen to eliminate oxidative and 
pyrolytic effect at a standard heating rate (10
◦
C/minute) on DSC. Over a temperature 
range, this will encompass any thermal changes due to the mixture of drug with 
polymers. Thermograms of pure drug are used as a reference.      
Appearance or disappearances of one or more peaks in thermograms of drug 
with polymer are considered as a indication of interaction. 
8.6. Scanning electron microscopy (SEM) (Chinna Gangadhar., et al.,2010) 
               The samples for the SEM analysis were prepared by sprinkling the 
microspheres on one side of a double adhesive stub. The stub was then coated with 
gold. The microspheres were then observed with the scanning electron microscope 
(SEM, JSM-6360LV scanning electron microscope, Tokyo, Japan) at 15kv.  The 
samples include blank microspheres, drug loaded microspheres. 
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8.7. In-vitro Release Study     (Karthikeyan., et al.,2003) 
                 In  vitro drug  release  from microspheres was performed using  the  
rotating  basket  method  as  specified  in  USP XXIV (Electro Lab, Mumbai). 
Microspheres equivalent  to  100 mg  of Metoprolol tartrate  was placed into basket 
(tied using- muslin cloth) immersed  in  900 ml  of 0.1  N  HCl (pH 1.2)  dissolution 
medium and  allowed  to rotated at 100 rpm. Operating temperature was maintained at 
37
o
 ± 1
o
C. Sample (5ml) was withdrawn at predetermined time hour intervals up to 
2hr. same volume was replaced to maintain sink condition. After 2hr, dissolution 
medium was changed by 900ml of fresh phosphate buffer of pH 7.4 and study was 
continued upto 12
th
 hour. The samples were analyzed by UV-spectrophotometer at 
274.5 nm.  
8.8. Kinetic of In-vitro drug release (Mohan raj Palanisamy., et al., 2009)        
 Five kinetic models including the zero order (Equation 1), first order 
(Equation 2), Higuchi matrix (Equation 3) and Peppas-Korsmeyer (Equation 4) 
release equations were applied to process the In-vitro released data to find the 
equation with the best fit using Microsoft Office Excel 2007. 
     
 
 
 
Equation 1 
Equation 2 
Equation 3 
Equation 4 
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Where R and UR are the released and unreleased percentages, respectively, at 
time (t); k1, k2, k3 and k4 are the rate constants of zero-order, first-order, Higuchi 
matrix, Peppas-Korsmeyer respectively. 
Table 8.1: Diffusion exponent and solute release mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
< 0.5 Quasi-Fickian diffusion 
0.5 Fickian diffusion 
0.5 < n < 1.0 Anomalous (non-Fickian) diffusion 
1.0 Case-II transport 
> 1.0 Super case-II transport 
 
8.8. STABILITY STUDY    (Manavalan R. and Ramasamy S., 2004) 
In any rational drug design or evaluation of dosage forms for drugs, the 
stability of the active component must be a major criterion in determining their 
acceptance or rejection. Stability of a drug can be defined as the time from the date of 
manufacture and the packaging of the formulation, until its chemical or biological 
activity was not less than a predetermined level of labeled potency and its physical 
characteristics have not changed appreciably or deleteriously. 
 Objective of the study 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
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requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted. The International Conference on Harmonization (ICH) 
Guidelines titled Stability testing of New Drug Substances and Products describes the 
stability test requirements for drug registration application in the European Union, 
Japan and the States of America. 
ICH specifies the length of study and storage conditions 
  Long-Term Testing: 2
◦ 
C ±2◦
 
C at 60% RH ±5% for 12 Months 
  Accelerated Testing: 40◦ C ±2◦
 
C at 75% RH ±5% for 6 Months  
The selected formulation F3 was exposured  up to 3 months of stability studies 
at accelerated condition (40
◦ 
C ±2
◦
C at 75% RH ± 5%RH) to find out the effect of  
percentage yield, drug content, entrapment efficiency and In-vitro drug release.  
Procedure: 
Stability studies were carried out at 40
°
C / 75% RH for the optimized 
formulation for 3 months. The microspheres were stored at 40
°
C/75% RH as per ICH 
guidelines and various parameters (drug content and drug release profile) were 
monitored periodically for 3 months. 
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9. RESULTS AND DISCUSSION 
 
 9.1. Identification of Drug:-  
 
9.1.1. Organoleptic Properties:
 
 Colour        :  White  
 Odour         : Odorless 
 Taste           : Metallic  
             Appearance: Fine powder 
9.1.2. Melting Point:
 
Melting point values of Metoprolol tartrate sample was found to be in range of 
136.4
0
C. The official melting point range is between136-138°C. Hence, results were 
complied the limits specified in official monographs. 
9.1.3. Solubility Study:
 
     Table 9.1: The solubility of Metoprolol tartrate in different solvents 
 
 
 
 
 
 
 
 
 
 
Name of solvent Parts of solvent required 
per part of solute 
Solubility 
Distilled water 10 Very soluble 
Ethanol (95%) 40 Freely soluble 
Chloroform 400 Sparingly soluble 
Ether 600 Practically 
insoluble 
0.1 N HCl 10 Very soluble 
Phosphate buffer 
pH7.4 
70 Freely soluble 
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9.1.4.1. UV Spectroscopy (λ max): 
9.1.4.1. Determination of λ max of Metoprolol tartrate by using Distilled Water 
The absorption maximum for Metoprolol tartrate in Distilled Water was 
found to be 274.5nm and it is shown in Figure 9.1. 
 
  
 Fig. 9.1: λ max Observed for Metoprolol tartrate in Distilled Water 
 
9.1.4.2. Preparation of Standard Curve of Metoprolol tartrate by using 
Distilled Water: 
 
UV absorption spectrum of Metoprolol tartrate in Distilled Water showed 
λ max at 274.5 nm. Absorbance obtained for various concentrations of Metoprolol 
tartrate in distilled water are given in Table 9.2. The graph of absorbance vs. 
concentration for Metoprolol tartrate was found to be linear in the concentration 
range of 10 - 50 µg/ml. The drug obeys Beer - Lambert’s law in the range of 10- 
60μg/ml which is shown in Figure 9.2.   
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Table 9.2: Data of concentration and absorbance for Metoprolol tartrate for 
Distilled Water 
 
 
S. No. 
   Concentration  
 
(µg/ml) 
 
   Absorbance at   
       274.5nm 
1. 0 0 
2. 4 0.140 
3. 8 0.272 
4. 12 0.396 
5. 16 0.534 
6. 20 0.681 
 
 
 
 
   
 
 
     
 
 
 
Fig. 9.2: Standard graph of Metoprolol tartrate in Distilled Water 
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The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the Table 9.3. 
 
Table 9.3: Data for calibration curve parameters in Distilled Water 
     S. No. Parameters Values 
1. Correlation Coefficient (r) 0.9999 
2. Slope (m) 0.0134 
3. Intercept (c) 0.0006 
 
9.1.4.3. Determination of λ max of Metoprolol tartrate by using 0.1N HCl: 
The absorption maximum for Metoprolol tartrate in 0.1N HCl was 
found to be    274.5 nm and it is shown in Figure 9.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig 9.3: λ max Observed for Metoprolol tartrate in 0 .1 N HCl 
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9.1.4.4. Preparation of Standard Curve of Metoprolol tartrate by using 0.1N HCl: 
 
      The UV absorption spectrum of Metoprolol tartrate in 0.1N HCl shows λ max at 
274.5 nm. Absorbance obtained for various concentrations of Metoprolol tartrate 
in 0.1 N HCl are given in Table 9.4. The graph of absorbance vs. concentration for 
Metoprolol tartrate was found to be linear in the concentration range of 10-50μg 
/ml. The drug obeys Beer - Lambert’s law in the range of 10-50 μg /ml.  This is 
shown in Figure 9.4 the calibration parameters were shown in Table 9.5. 
Table 9.4: Data of concentration and absorbance for Metoprolol tartrate for 0.1N HCl 
 
 
S. No. 
    
    Concentration (µg/ml) 
 
Absorbance at 274.5 nm    
1. 0 0.000 
2.                 10 0.136 
3.                  20 0.276 
4.          30 0.419 
5. 40 0.557 
6. 50 0.690 
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Fig.9.4 : Standard graph  of Metoprolol tartrate 0.1N HCl 
The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the Table 9.5. 
 Table 9.5: Data for calibration curve parameters in 0.1N HCl 
 
  
S. No. Parameters Values 
1
. 
Correlation Coefficient (r) 0.9999 
2
. 
Slope (m) 0.0138 
3
. 
Intercept (c) 0.0003 
 
 
 
 
 
 
 
Controlled Release Microspheres of Metoprolol tartrate   Results and Discussion 
 
Adhiparasakthi college of pharmacy, Melmaruvathur Page 91 
 
9.1.4.5. Determination of λ max of Metoprolol tartrate by using pH 7.4 Phosphate 
buffer: 
 The absorption maximum for Metoprolol tartrate in pH phosphate buffer was found 
to be 274.5 nm and it is shown in Figure 9.5 
 
 
  
Fig 9.5:  λ max Observed for Metoprolol tartrate in Phosphate buffer pH 7.4   
9.1.4.6. Preparation of standard curve of Metoprolol tartrate by using pH 7.4 
Phosphate Buffer:   
UV absorption spectrum of Metoprolol tartrate pH 7.4 phosphate buffer shows 
λ max at 274.5 nm. Absorbance obtained for various concentrations of Metoprolol 
tartrate in pH phosphate Buffer are given in table 9.6. The graph absorbance vs 
concentration for Metoprolol tartrate was found to be linear in the concentration range 
of 10-50 μg /ml.  The  drug obeys Beer- Lambert’s law in the range of 10-50 μg /ml 
which is shown in Figure 9.7 
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Table 9.6 :Data of concentration and Absorbance data for Metoprolol tartrate in pH 
7.4 Phosphate Buffer  
S. No. 
Concentration 
(μg/ml) 
 
Absorbance at 274.5 nm 
 
1 0 
0 
 
2 10 
                  0.132 
 
3 20 
0.263 
 
4 30 
0.401 
 
5 40 
0.526 
 
6 50 
0.657 
 
       
 
    
 
 
Fig. 9.6: Standard graph of Metoprolol tartrate pH 7.4 Phosphate buffer 
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Table 9.7:  Data for Calibration Curve parameters in pH 7.4 Phosphate Buffer  
    The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the following table 9.7. 
 
S. No. Parameters Values 
1 Slope 0.0131 
2 Intercept 0.0006 
3 Correlation coefficient (R) 0.9996 
 
9.1.5. Quantification of Drug: 
             
The percentage purity of drug was calculated by using calibration graph 
method (least square method) and the data has been shown in table 9.8. 
                                                                                                                                        
Table 9.8: Percentage purity of Metoprolol tartrate 
 
 
S. No. Percentage Purity (%) Average Percentage Purity* (%) 
1. 99.44  
 
 
99.67 ± 0.17 2. 99.71 
3. 99.83 
                           *All the values are expressed as mean ± SD, n = 3 
 
 
The percentage purity for Metoprolol tartrate in IP 2007 is not less than 90.0 % 
and not more than 101.0 % of the stated amount of Metoprolol tartrate. The 
percentage purity of Metoprolol tartrate was found to be 99.67 ± 0.17. So, it 
stands within the limits of IP 2007 
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9.1.6. Fourier Transform Infra-Red Spectroscopy (FTIR): 
The FTIR spectrum of Metoprolol tartrate shown in figure  9.7. The 
Interpretation of IR frequencies are shown in Table 9.9. 
 
Fig. 9.7: FTIR Spectrum of Metoprolol Tartrate 
       Table 9.9: Interpretation of FTIR spectra of Metoprolol tartrate 
O-H Stretching  3752.18 
C-O-C Stretching Aliphatic 1114.34 
C- N Stretching 1242.27 
N-H bend Aliphatic 1615.06 
N-H Stretch 2 Amine 3151.25 
From the above figure 9.9, it can be seen that, the major functional group 
peaks observed in spectras of Drug with all the polymers remains unchanged as 
compared with spectra of Metoprolol tartrate. So fom the above FTIR spectra it can 
be observed that the identified as Metoprolol tartrate. 
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9.1.7. Loss on drying 
The percentage loss on drying after 5 hours was found to be 0.208±0.003%. 
The sample passes test for loss on drying as per the limits specified in IP.  
Table 9.10: Loss on drying of Metoprolol tartrate 
S. No. Percentage Loss on drying 
(%) 
Average LOD 
(%) 
1 0.205  
0.208±0.003 2 0.206 
3 0.214 
All the values are expressed as a mean  SD., n = 3 
9.2. EVALUATION OF MICROSPHERES 
 9.2.1. Percentage Yield, Drug Content and Entrapment Efficiency 
The percentage yield, Drug Content and Entrapment Efficiency of Controlled 
release microspheres were found to increased as the polymer ratio was increased. The 
maximum yield of microspheres was 87.16% in Egg albumin polymer, 80.48% in 
Ethyl cellulose and 83.48% in Eudragit RL 100. Better yield of microspheres was 
obtained from Egg albumin. Drug content and Entrapment efficiency was high in Egg 
albumin containing formulations when compared to Ethyl cellulose and Eudragit RL 
100 formulations. All the formulations Percentage Yield, Drug content and 
Entrapment efficiency data was showed in Table 9.11. 
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Table 9.11: Comparison of Percentage yield, Drug content and Percentage 
Entrapment efficiency 
 
S. No. FORMULATIONS % YIELD 
% DRUG 
CONTENT 
% 
ENTRAPMENT 
1 F1 84.76 53.35±0.94 83.08±1.62 
2 F2 87.90 56.81±1.31 85.12±1.21 
3 F3 90.37 63.61±1.71 88.40±1.08 
4 F4 78.38 36.76±1.59 72.49±1.20 
5 F5 82.53 38.09±1.57 76.04±1.23 
6 F6 86.46 46.15±1.50 79.42±0.41 
7 F7 81.61 45.01±1.36 74.84±1.46 
8 F8 83.17 47.92±1.81 77.89±0.36 
9 F9 86.98 51.08±1.25 81.79±1.32 
 
  
 
Figure 9.8: Percentage Yield, Drug Content and Entrapment Efficiency 
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9.2.2. Particle size analysis 
 Particle size of prepared microspheres was determined by optical microscopy 
method and the average particle sizes of all batches of microspheres were represented 
in Table. 9.12. 
 All the batches of microspheres were prepared by keeping the drug amount 
and solvent volume constant. The particle sizes of the sustained release microspheres 
were found to be in the range of 50±0.05 µm – 335±0.32 µm. The results were 
represented graphically in Figure 9.9. 
Table 9.12: particle size for various formulations of microspheres 
S.NO Formulation  
Code 
Particle size 
(µm±S.D) 
1 F1 50±0.50 
2 F2 93±0.32 
3 F3 98±0.41 
4 F4 215±0.45 
5 F5 277±0.43 
6 F6 335±0.32 
7 F7 116±0.34 
8 F8 160±0.54 
9 F9 225±0.36 
 
                            All the values are expressed as a mean  SD., n = 3 
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 Figure 9.9: Mean Particles size 
 
9.2.3. DRUG - POLYMERS COMPATIBILITY STUDIES: 
9.2.3.1. Fourier Transform Infra-Red Spectroscopy (FTIR): 
 
   
Fig 9.10: FTIR spectrum of pure drug Metoprolol Tartrate 
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         Fig 9.11: FTIR spectrum of Metoprolol Tartrate and Egg albumin 
  
                                                                                                                                                                                                                             
 
       Fig 9.12: FTIR spectrum of Metoprolol Tartrate and Ethyl cellulose 
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 Fig 9.13: FTIR spectrum of Metoprolol tartrate and Eudragit RL 100 
 
 The possible drug and polymer interaction can be studied by FTIR 
spectroscopy. According to the Figure 9.10 and Figure 9.13 the major peaks observed 
in drug spectrum were also observed in spectrum of drug with polymer, therefore it 
could it could indicate that there is no in compatibility between drug and polymer.    
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  9.2.3.2. Drug – polymer compatability    
 
Fig.9.14: DSC Curve of Pure Metoprolol tartrate 
 
Fig.9.15: DSC Curve of Metoprolol tartrate and Egg albumin 
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Fig.9.16: DSC Curve of Metoprolol tartrate and Ethyl cellulose 
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Table 9.13: Data for DSC thermogram parameters 
 
S.NO 
DSC thermogram 
sample 
Onset 
temperature 
(°C) 
Peak 
Temperature 
(°C) 
1 Metoprolol tartrate 140.94 145.33 
2 Metoprolol tartrate 
+Egg albumin 
129.93 140.36 
3 Metoprolol tartrate 
+Ethyl cellulose 
138.46 144.79 
  
9.2.4. Scanning Electron Microscopy Analysis (Surface morphology) 
 Surface morphology and shape characteristics of microspheres were evaluated 
by means of scanning electron microscopy. The SEM photographs of the 
microspheres revealed that the microspheres were spherical with rough, hollow 
surface and slightly aggregated were showed in Figure 9.17 and 9.18.  
                               
Figure 9.17: Scanning electron microphotograph of formulation F3 at lower                
Magnification 
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Figure 9.18: Scanning electron microphotograph of formulation F3 at higher   
 
Magnification 
 
9.3. In-vitro Dissolution studies 
In-vitro drug released profiles of Metoprolol tartrate microspheres were 
performed in each formulation up to 2 hours in 0.1N HCl followed by phosphate 
buffer (pH 7.4) up to 12 hours. It was represented in Table 9.24 and showed in Figure 
9.19 to 9.27. 
Table 9.14: Parameters were used for the dissolution study 
Apparatus  USP type II apparatus (Basket  
type)  
Temperature  37 +  0.5° C  
Total Volume  900ml  
Speed  100 rpm  
Drawn volume  5 ml  
Running time  2 hrs in 0.1N HCl and 10 hrs in phosphate 
buffer pH 7.4.  
Medium Replacement  Medium refilling at 2 hrs  
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Table 9.15: In-vitro drug release data of formulation F1 
                               
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 11.46±0.70 11.46 5.94 0.25 
1 20.22±1.35 20.22 11.30 0.47 
2 26.31±1.42 26.31 17.99 0.71 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
30.59±1.95 30.59 21.83 0.89 
4 33.70±0.97 33.70 24.63 1.19 
5 39.40±1.04 39.40 27.23 1.62 
6 47.30±1.04 47.30 30.07 2.27 
7 52.58±1.94 52.58 33.07 2.70 
8 57.04±1.20 57.04 35.96 3.09 
9 61.21±1.97 61.21 38.73 3.48 
10 70.32±1.04 70.32 41.64 4.26 
11 76.04±1.23 76.04 44.72 4.74 
12 81.77±1.76 81.77 47.80 5.23 
 
     * All the values expressed as mean ± mean S.D., n=3   
  
 
   
 
 
Fig. 9.19: In-vitro drug release profile of formulation F1 
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Table 9.16: In-vitro drug release data of formulation F2 
                               
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 12.45±1.01 12.45 6.57 0.25 
1 21.01±0.98 21.01 12.13 0.45 
2 28.64±0.83 28.64 19.21 0.73 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
31.96±1.54 31.96 23.27 0.85 
4 36.43±1.95 36.43 26.15 1.18 
5 42.27±1.76 42.27 28.94 1.64 
6 48.33±1.20 48.33 31.82 2.13 
7 52.57±1.89 52.57 34.64 2.50 
8 56.47±1.27 56.47 37.31 2.86 
9 61.50±1.29 61.50 39.92 3.34 
10 73.18±1.29 73.18 42.87 4.32 
11 79.07±0.69 79.07 46.11 4.80 
12 83.60±1.24 83.60 49.29 5.17 
 
     * All the values expressed as mean ± mean S.D., n=3 
 
 
 
 
                                                         
Fig 9.20: In-vitro drug release profile of formulation F2 
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                Table 9.17: In-vitro drug release data of formulation F3 
                               
       * All the values expressed as mean ± mean S.D., n=3 
 
 
 
 
                   
 
Fig 9.21: In-vitro drug release profile of formulation F3 
 
              
 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 14.27±1.61 14.27 7.60 0.25 
1 28.92±0.98 28.92 15.24 0.50 
2 32.39±0.68 32.39 23.87 0.61 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
36.08±1.10 36.08 27.75 0.73 
4 40.43±1.95 40.43 30.55 1.03 
5 44.78±1.57 44.78 33.17 1.40 
6 51.66±1.23 51.66 35.89 1.93 
7 54.98±0.39 54.98 38.57 2.22 
8 58.30±0.39 58.30 41.03 2.54 
9 66.20±1.88 66.20 43.60 3.25 
10 75.70±1.03 75.70 46.56 4.04 
11 80.39±1.20 80.39 49.68 4.46 
12 86.72±1.19 86.72 52.78 4.97 
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 Table 9.18: In-vitro drug release data of formulation F4 
  
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 8.81±0.82 8.81 4.68 0.25 
1 11.52±0.68 11.52 7.75 0.37 
2 18.03±0.79 18.03 11.77 0.78 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
24.06±0.20 24.06 15.14 1.14 
4 27.38±0.86 27.38 17.90 1.43 
5 30.70±1.57 30.70 20.24 1.77 
6 34.80±0.71 34.80 22.39 2.16 
7 39.99±1.40 39.99 24.64 2.82 
8 42.91±0.75 42.91 26.90 3.13 
9 48.68±1.55 48.68 26.15 3.76 
10 57.15±0.59 57.15 31.69 4.62 
11 61.51±1.59 68.51 34.37 5.04 
12 69.51±1.20 69.51 37.11 5.72 
 * All the values expressed as mean ± mean S.D., n=3 
 
 
 
 
 
 
               
 Fig 9.22: In-vitro drug release profile of formulation F4
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Table 9.19: In-vitro drug release data of formulation F5 
  
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 10.11±0.69 10.11 19.76 0.25 
1 16.53±0.86 16.53 21.62 0.37 
2 18.93±1.30 18.93 22.06 0.40 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
24.86±0.68 24.86 23.44 0.78 
4 88.98±0.90 88.98 24.18 0.84 
5 35.59±0.90 35.59 25.37 1.52 
6 42.46±1.14 42.46 27.80 2.16 
7 48.58±1.56 48.58 30.49 2.73 
8 53.60±0.86 53.60 33.25 3.17 
9 56.99±0.79 56.99 35.88 3.50 
10 60.24±0.91 60.24 38.34 3.85 
11 66.20±1.20 66.20 40.81 4.46 
12 70.09±1.69 70.09 43.31 4.87 
* All the values expressed as mean ± mean S.D., n=3 
 
 
 
 
Fig 9.23: In-vitro drug release profile of formulation F5 
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     Table 9.20: In-vitro drug release data of formulation F6 
                               
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 10.98±1.17 10.98 5.83 0.25 
1 19.35±0.49 19.35 10.95 0.47 
2 21.96±1.31 21.96 16.45 0.59 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
26.27±1.27 26.27 19.31 0.83 
4 29.57±1.91 29.57 21.59 1.14 
5 33.79±1.23 33.79 23.74 1.56 
6 37.33±0.87 37.33 25.85 1.95 
7 43.24±1.81 43.24 28.18 2.71 
8 51.86±1.88 51.86 20.82 3.31 
9 57.50±1.03 57.50 33.67 3.99 
10 60.84±1.23 60.84 36.50 4.25 
11 67.11±0.59 67.11 39.22 4.78 
12 74.10±0.19 74.10 42.04 5.42 
* All the values expressed as mean ± mean S.D., n=3 
 
         
 
 
 
Fig 9.24: In-vitro drug release profile of formulation F6 
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 Table 9.21: In-vitro drug release data of formulation F7 
                               
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 10.87±1.67 10.87 5.77 0.25 
1 16.63±1.04 16.63 10.18 0.42 
2 19.35±0.99 19.35 14.66 0.58 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
24.18±0.69 24.18 17.31 0.89 
4 27.84±1.62 27.84 19.61 1.24 
5 32.42±0.91 32.42 21.84 1.70 
6 39.52±0.86 39.52 24.32 2.39 
7 46.76±0.37 46.76 37.15 3.02 
8 53.72±0.34 53.72 30.18 3.61 
9 56.69±0.71 56.69 33.12 3.89 
10 59.67±1.38 59.67 35.80 4.19 
11 67.23±0.39 67.23 38.50 4.90 
12 72.49±1.20 72.49 41.32 5.40 
* All the values expressed as mean ± mean S.D., n=3 
 
 
 
 
 
Fig 9.25: In-vitro drug release profile of formulation F7 
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Table 9.22: In-vitro drug release data of formulation F8 
                               
Time 
(hours) 
 
pH Medium DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 11.63±1.30 11.63 6.17 0.25 
1 18.15±0.86 18.15 10.98 0.27 
2 21.09±0.98 21.09 31.85 0.43 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal fluid) 
26.47±1.31 26.47 36.80 0.90 
4 29.57±1.22 29.57 37.33 0.96 
5 37.80±1.10 37.80 37.64 1.26 
6 43.53±1.38 43.53 39.16 1.42 
7 50.17±0.52 50.17 40.14 1.70 
8 56.69±1.20 56.69 41.14 2.37 
9 59.67±1.38 59.67 43.25 2.70 
10 66.77±0.68 66.77 45.47 3.43 
11 70.89±0.68 70.89 47.83 3.86 
12 74.34±1.90 74.34 50.14 4.24 
* All the values expressed as mean ± mean S.D., n=3 
 
 
 
 
      Fig 9.26: In-vitro drug release profile of formulation F8 
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 Table 9.23: In-vitro drug release data of formulation F9 
                               
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 12.29±1.63 12.29 6.51 0.25 
1 19.24±0.99 19.24 11.61 0.43 
2 24.46±1.31 24.46 17.41 0.66 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
29.10±0.19 29.10 20.87 0.88 
4 32.65±1.10 32.65 23.50 1.17 
5 39.71±1.46 39.71 26.18 1.77 
6 46.85±0.69 46.85 29.18 2.34 
7 50.40±0.19 50.40 32.12 2.65 
8 57.04±0.52 57.04 34.99 3.22 
9 60.24±0.91 60.24 37.80 3.52 
10 66.20±1.20 66.20 40.54 4.07 
11 69.75±0.39 69.75 43.25 4.41 
12 76.05±1.49 76.05 45.94 5.01 
      * All the values expressed as mean ± mean S.D., n=3 
  
                  
   
 
   
Fig 9.27: In-vitro drug release profile of formulation F9
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Table 9.24: Comparative drug release data for all formulations 
 
 
Time in 
hours 
 
pH 
Medium 
Formulations 
F1 
% 
F2 
% 
F3 
% 
F4 
% 
F5 
% 
F6 
% 
F7 
% 
F8 
% 
F9 
% 
 
0.5 
 
1 
 
2 
 
       
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
 
pH 1.2         
(simulated                  
gastric 
fluid) 
 
11.46±0.70 
 
20.22±1.35 
 
26.31±1.42 
 
12.45±1.01 
 
21.01±0.98 
 
28.64±0.83 
 
14.27±1.61 
 
28.92±0.98 
 
32.39±0.68 
 
8.81±0.82 
 
11.52±0.68 
 
18.03±0.79 
 
10.11±0.69 
 
16.53±0.86 
 
18.93±1.30 
 
10.98±1.17 
 
19.35±0.49 
 
21.96±1.31 
 
10.87±1.67 
 
16.63±1.04 
 
19.35±0.99 
 
11.63±1.30 
 
18.15±0.86 
 
21.09±0.98 
 
 
12.29±1.63 
 
19.24±0.99 
 
24.46±1.31 
 
 
 
pH 7.4 
(simulated 
intestinal 
fluid) 
 
30.59±1.95 
 
33.70±0.97 
 
39.40±1.04 
 
47.30±1.04 
 
52.58±1.94 
 
57.04±1.20 
 
61.21±1.97 
 
70.32±1.04 
 
76.04±1.23 
 
81.77±1.76 
 
31.96±1.54 
 
36.43±1.95 
 
42.27±1.76 
 
48.33±1.20 
 
52.57±1.89 
 
56.47±1.27 
 
61.50±1.29 
 
73.18±1.29 
 
79.07±0.69 
 
83.60±1.24 
 
36.08±1.10 
 
40.43±1.95 
 
44.78±1.57 
 
51.66±1.23 
 
54.98±0.39 
 
58.30±0.39 
 
66.20±1.88 
 
75.70±1.03 
 
80.39±1.20 
 
86.72±1.19 
 
24.06±0.20 
 
27.38±0.86 
 
30.70±1.57 
 
34.80±0.71 
 
39.99±1.40 
 
42.91±0.75 
 
48.68±1.55 
 
57.15±0.59 
 
61.51±1.59 
 
69.51±1.20 
 
24.86±0.68 
 
88.98±0.90 
 
35.59±0.90 
 
42.46±1.14 
 
48.58±1.56 
 
53.60±0.86 
 
56.99±0.79 
 
60.24±0.91 
 
66.20±1.20 
 
70.09±1.69 
 
 
26.27±1.27 
 
29.57±1.91 
 
33.79±1.23 
 
37.33±0.87 
 
43.24±1.81 
 
51.86±1.88 
 
57.50±1.03 
 
60.84±1.23 
 
67.11±0.59 
 
74.10±0.19 
 
24.18±0.69 
 
27.84±1.62 
 
32.42±0.91 
 
39.52±0.86 
 
46.76±0.37 
 
53.72±0.34 
 
56.69±0.71 
 
59.67±1.38 
 
67.23±0.39 
 
72.49±1.20 
 
26.47±1.31 
 
29.57±1.22 
 
37.80±1.10 
 
43.53±1.38 
 
50.17±0.52 
 
56.69±1.20 
 
59.67±1.38 
 
66.77±0.68 
 
70.89±0.68 
 
74.34±1.90 
 
29.10±0.19 
 
32.65±1.10 
 
39.71±1.46 
 
46.85±0.69 
 
50.40±0.19 
 
57.04±0.52 
 
60.24±0.91 
 
66.20±1.20 
 
69.75±0.39 
 
76.05±1.49 
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Fig.9.28: Comparitive drug release profile between F1 to F3 
 
 
Fig.9.29: Comparitive drug release profile between F4 to F6 
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Fig.9.30: Comparitive drug release profile between F7 to F9 
 
           Fig 9.31: Comparative drug release profile between formulation F1 – F9 
After completing the dissolution study in 0.1 N HCl (900ml) for first two 
hours and the dissolution study was continued in the phosphate buffer pH 7.4 up to 
the twelve hours. The drug release from formulation F1, F2 and F3 containing Egg 
albumin (1:1, 1:2 and 1:3) alone was found to be 81.77%, 83.60% and 86.72% % after 
the end of 12 hrs. This is due to higher solubility of drug in the medium.  
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The drug released from formulation F4, F5 and F6 containing Ethyl cellulose 
(1:1, 1:2 and 1:3) were 69.51%, 70.09% and 74.10% respectively at the end of 12 hrs. 
The drug released from formulation F7, F8 and F9 containing Eudragit RL100 
(1:1, 1:2 and1:3) were 72.49%, 74.34% and 76.05% respectively at the end of 12 hrs. 
The drug released from formulation F3containing Egg albumin was found to be 
86.72% at the end of 12 hrs, which is showing high percentage drug release.  
9.4. Kinetics of In-Vitro Drug Release:  
 The drug diffusion through most type of polymeric system is often best 
described by Fickian diffusion (diffusion exponent, n=0.5), but other process in 
addition to diffusion are important. There is also a relaxation of the polymer chain, 
which influences the drug release mechanism. This process is described as non- 
fickian or anomalous diffusion (n=0.5-1.0).  Release from initially dry, hydrophilic 
glassy polymer that swell when added to water and become rubbery, show anomalous 
diffusion as a result of the rearrangement of macromolecular chain. The 
thermodynamics state of the polymer and penetrant concentration are responsible for 
the different type of the diffusion. A third class of diffusion is case-II diffusion (n=1), 
which is a special case of non- Fickian diffusion. To obtain kinetic parameter of 
dissolution profile, data were fitted to different kinetic models. 
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  Table 9.25: Kinetics of in-vitro drug release profile for all Formulation 
 
 
 
 
Formulation 
code 
Zero 
orde
R
2
 
R2 value 
First 
orde
R
2
 
R2 value 
 
 
Higuchi’s 
 
R2 value 
Peppas  
 
 
 
Best fit 
 
 
R2 value 
 
 
n value 
F1 0.823 0.824 0.983 0.974 0.389    Matrix 
F2 0.835 0.835 0.984 0.974 0.390    Matrix 
F3 0.847 0.847 0.987 0.978 0.397    Matrix 
F4 0.838 0.838 0.970 0.953 0.349    Matrix 
F5 0.848 0.848 0.976 0.970 0.366 Matrix 
F6 0.860 0.860 0.981 0.970 0.388    Matrix 
F7 0.821 0.821 0.974 0.953 0.381    Matrix 
F8 0.860 0.860 0.980 0.963 0.384    Matrix 
F9 0.862 0.862 0.981 0.976 0.390 Matrix 
 
 
 
 
                   
 
Fig. 9.32: Best fit model for formulation F1 (Matrix) 
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Fig. 9.33: Best fit model for formulation F2 (Matrix) 
 
 
Fig. 9.34: Best fit model for formulation F3 (Matrix) 
 
Fig. 9.35: Best fit model for formulation F4 (Matrix) 
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Fig. 9.36: Best fit model for formulation F5 (Matrix) 
 
 
       Fig. 9.37: Best fit model for formulation F6 (Matrix) 
 
 
 Fig. 9.38: Best fit model for formulation F7 (Matrix) 
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                    Fig. 9.39: Best fit model for formulation F8 (Matrix) 
 
    
   Fig. 9.40: Best fit model for formulation F9 (Matrix) 
For microspheres, an ―n‖ value near to 0.5 indicates diffusion control and an ―n‖ value 
near to 1 indicates relaxation or erosion control. The intermediate value suggests that diffusion 
and erosion contributes to overall release mechanism. It was also observed that highest  
correlation was found for Matrix Square root time profile (R
2
 > 0.5), which indicates the drug 
release via diffusion mechanism from all formulations. 
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9.5. STABILITY STUDY 
From the results of the above studies it was found that formulation F3 was considered as 
the best formulation amongst the nine formulations. Hence formulation F3 was selected for 
stability studies.  
9.5.1. Stability studies at the end of First month (30 days): 
9.5.1.1. Drug content:  
 The Percentage drug content of microspheres after one month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 9.26. 
 
 Table 9.26: Drug content of formulation F3 at the end of 1 month of stability 
S. No. Formulation Percentage drug content 
1. F3          63.58±0.030 
                          All the values are expressed as a mean  SD., n = 3 
 
9.5.1.2. Entrapment Efficiency:  
 The Entrapment efficiency of microspheres after one month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 9.27. 
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Table 9.27: Entrapment efficiency of formulation F3 at the end of 1 month of stability 
S. No. Formulation Entrapment efficiency (%) 
1. F3          88.37±0.030 
                    All the values are expressed as a mean  SD., n = 3 
9.5.1.3. In-vitro drug release study:  
 The Percentage Drug Release from F3 microspheres after one month of stability was 
studied. The data is shown in Table 9.28 
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   Table 9.28:  In-vitro drug release data of formulation F3 at the end of 1 month of stability 
    
            
Fig.9.41: Stability study (In-vitro drug release) of formulation F3 at the end of 1 month 
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Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 14.27±1.61 14.27 7.60 0.25 
1 28.92±0.98 28.92 15.24 0.50 
2 32.39±0.68 32.39 23.87 0.61 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
36.08±1.10 36.08 27.75 0.73 
4 40.43±1.95 40.43 30.55 1.03 
5 44.78±1.57 44.78 33.17 1.40 
6 51.66±1.23 51.66 35.89 1.93 
7 54.98±0.39 54.98 38.57 2.22 
8 58.30±0.39 58.30 41.03 2.54 
9 66.20±1.88 66.20 43.60 3.25 
10 75.70±1.03 75.70 46.56 4.04 
11 80.39±1.20 80.39 49.68 4.46 
12 86.72±1.19 86.72 52.78 4.97 
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9.5.2. Stability studies at the end of Second month (60 days): 
9.5.2.1. Drug content:  
The Percentage drug content of microspheres after Two months of stability studies was 
studied. The results are within the official limits. The data is shown in Table 9.29. 
    Table 9.29: Drug content of formulation F3 at the end of 2 months of stability 
S. No. Formulation Percentage drug content 
1. F3 63.54±0.025 
        All the values are expressed as a mean  SD., n = 3 
 
   9.5.2.2. Entrapment efficiency:  
 The Entrapment efficiency of microspheres after Two months of stability studies 
was studied. The results are within the official limits. The data is shown in Table 9.30. 
 
 Table 9.30: Entrapment efficiency of formulation F3 at the end of 2 months of   stability 
S. No. Formulation Entrapment efficiency (%) 
1. F3 88.35±0.025 
        All the values are expressed as a mean  SD., n = 3 
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9.5.2.3. In-vitro drug release study:  
 The Percentage Drug Release from F3 microspheres after Two months of stability 
was studied. The data is shown in Table 9.31. 
 Table 9.31: In-vitro drug release data of formulation F3 at the end of 2 months of stability 
 
    Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 14.27±1.61 14.27 7.60 0.25 
1 28.92±0.98 28.92 15.24 0.50 
2 32.39±0.68 32.39 23.87 0.61 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
36.08±1.10 36.08 27.75 0.73 
4 40.43±1.95 40.43 30.55 1.03 
5 44.78±1.57 44.78 33.17 1.40 
6 51.66±1.23 51.66 35.89 1.93 
7 54.98±0.39 54.98 38.57 2.22 
8 58.30±0.39 58.30 41.03 2.54 
9 66.20±1.88 66.20 43.60 3.25 
10 75.70±1.03 75.70 46.56 4.04 
11 80.39±1.20 80.39 49.68 4.46 
12 86.72±1.19 86.72 52.78 4.97 
                         All the values are expressed as a mean  SD., n = 3 
 
   Fig.9.42 Stability study (In-vitro drug release) of formulation F3 at the end of 2 month 
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9.5.3. Stability studies at the end of Third month (90 days): 
9.5.3.1. Drug content:  
 The Percentage drug content of microspheres after Third month of stability studies was 
studied. The results are within the official limits. The data is shown in Table 9.32. 
       Table 9.32: Drug content of formulation F3 at the end of 3 months of stability 
 S. No. Formulation Percentage drug content 
1. F3 63.51±0.020 
       All the values are expressed as a mean  SD., n = 3 
9.5.3.2. Entrapment efficiency:  
 The Entrapment efficiency of microspheres after Third month of stability studies 
was studied. The results are within the official limits. The data is shown in Table 9.33. 
            Table 9.33: Entrapment efficiency of formulation F3 at the end of 3 months of stability 
 S. No. Formulation Entrapment efficiency(%) 
1. F3 88.30±0.020 
       All the values are expressed as a mean  SD., n = 3 
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9.5.3.3. In-vitro drug release study:  
 The Percentage Drug Release from F3 microspheres after Two months of stability 
was studied. The data is shown in Table 9.34. 
Table 9.34: In-vitro drug release data of formulation F3 at the end of 3 months of 
stability 
Time 
(hours) 
 
pH 
Medium 
DR* 
(%) 
Amount 
(mg) 
 
% DE 
 
MDT 
 
0 pH 1.2         
(simulated                  
gastric fluid) 
0.00 0.00 0.00 0.00 
0.5 12.45±1.01 12.45 6.57 0.25 
1 21.01±0.98 21.01 12.13 0.45 
2 28.64±0.83 28.64 19.21 0.73 
3  
 
 
 
pH 7.4         
(simulated                  
Intestinal 
fluid) 
31.96±1.54 31.96 23.27 0.85 
4 36.43±1.95 36.43 26.15 1.18 
5 42.28±1.76 42.28 28.96 1.64 
6 48.33±1.20 48.33 31.82 2.13 
7 52.54±1.89 52.57 34.64 2.50 
8 56.47±1.27 56.47 37.31 2.86 
9 61.50±1.29 61.50 39.92 3.34 
10 73.18±1.29 73.18 42.87 4.32 
11 79.07±0.69 79.07 46.11 4.80 
12 86.16±1.24 86.16 49.27 5.17 
 All the values are expressed as a mean  SD., n = 3 
 
      Fig.9.43. Stability study (In-vitro drug release) of formulation F3 at the end of 3month 
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Fig.9.44: Comparison of drug content for formulation F3 with initial and different 
periods of stability 
 
 
 
 
 
              Fig.9.45: Comparison of Entrapment efficiency for formulation F3 with initial 
and different periods of stability 
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Fig.9.46: Comparison of percentage drug released at the end of 12 hours for formulation 
F3 with initial and different periods of stability 
 
No statistically significant differences were observed in percentage drug content 
and percentage drug release in optimized formulation at the end of three months of 
stability studies. So it can be concluded that the formulation is stable for short term 
storage conditions. 
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10. SUMMARY AND CONCLUSION 
 The goal of any drug delivery system was to provide the therapeutic amount 
of drug to the proper site in the body also to achieve and maintain the desired drug 
concentration in blood. Improving the therapeutic efficacy of existing drugs has been 
tried by different technologies. One of the effective technologies exiting in recent 
years of pharmacy is Microspheres. 
 Controlled release drug delivery system was developed in pharmacy field and 
drug retention for a prolonged time has been achieved. Hence, it was made an 
effective attempt to formulate the Controlled release microspheres by Metoprolol 
tartrate as the model drug. 
 Metoprolol tartrate was the prototype of cardio selective (β1) blocker 
used in the treatment of several diseases cardiovascular system especially 
hypertension. Metoprolol tartrate possess the mean half life of five hours and 
bioavailability was found to be only 30-40 % and high water solubility Hence, it was 
chosen as the good candidate for the Controlled release microspheres in order to 
improve the bioavailability and prolong period of drug released. 
Controlled release microspheres of Metoprolol tartrate were successfully 
prepared by Emulsion polymerization and solvent evaporation technique was 
confirmed that it was a best method for preparing microspheres from its higher 
percentage yield. 
The identification of drug was carried out by FTIR spectroscopy and melting 
point. The physicochemical parameters such as appearance, solubility study and loss 
on drying were performed by suitable methods. The analytical profile of drug was  
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evaluated for determination of absorption maximum, development of standard curve 
and percentage purity of drug.  
Compatibility of drug and polymer mixture was done by performing DSC 
study. It was concluded that there was no interaction between the drug and polymer. 
Controlled release microspheres were obtained by solvent evaporation method for all 
the formulations from F1 to F9. Formulations F1, F2 and F3 were prepared 
Metoprolol tartrate with Egg albumin polymer in the ratio of 1: 1, 1: 2 and 1: 3. 
Similarly, formulations F4, F5 and F6 were prepared Metoprolol tartrate with Ethyl 
cellulose polymer in the ratio of 1:1, 1:2 and 1:3; and formulations F7, F8 and F9 
were prepared Metoprolol tartrate with Eudragit RL 100 polymer in the ratio of 1: 1, 
1: 2 and   1: 3. All formulations were evaluated for the Percentage yield, Drug 
content, Entrapment efficiency, Particle size, Scanning electron microscopy, and In-
vitro drug release study. 
On comparing the major criteria in evaluation such as percentage yield, drug 
content, entrapment efficiency and In-Vitro drug released profile, the formulation F3 
was selected as the best formulation, as it showed maximum percentage yield, drug 
content and Entrapment efficiency. It also showed a good Controlled drug release 
pattern up to 12 hrs.  
Based on all the above evaluation parameters it was concluded that the 
formulation F3 was found to be best formulation among the formulations from F1 to 
F9. The in-vitro drug released data was applied to various kinetic models such as zero 
order kinetics, Higuchi plot, first order kinetics and Peppas plot by predict the drug 
release kinetics mechanism. The formulation F3 was best fitted with Matrix kinetics 
and it undergoes Quasi-fickian diffusion mechanism (n<0.5).
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According to stability study it was found that there was no variation in 
Percentage yield, Entrapment efficiency, and In-vitro drug released profile of 
optimized formulation F3 for 3 months period. 
 From the overall studies it can be concluded that the formulation F3 
considered as the best formulation among nine formulations by comparing all the 
evaluated parameters.  
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11. FUTURE PROSPECTS 
 
In this work only physic-chemical characterization and in-vitro evaluation of 
Metoprolol tartrate were done.  
 Along with in-vitro release study in-vivo release studies are also important. So 
in future in-vivo release study using different models are required to set the in-
vitro / in-vivo correlation which is necessary for development of successful 
formulation and also long term stability studies are necessary. 
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